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Reactive oxygen species (ROS) are a ubiquitous part of human life having both 
beneficial and harmful effects. These are produced in cells under physiological conditions 
during the oxygen metabolism and other redox processes that are of vital importance for 
the biological function. However, excess of these radicals react with cellular lipids, 
proteins and nucleic acids leading to local injury and eventual organ dysfunction. 
Oxidative stress has a probable role in the pathogenesis of a variety of human diseases. 
Among ROS, hydroxyl radical is the most reactive oxidant. It is widely produced 
in many biological processes through Haber-Weiss, Fenton reactions or by ionizing 
radiations. It reacts to most biomolecules at diffusion controlled rates causing oxidative 
damage. DNA is a vulnerable and important target for .,. ^iJuced damage causing 
destruction of bases and deoxy-ribose sugars or single or double strand breaks. The 
oxidative damage to DNA is an important factor in mutagenesis and carcinogenesis. 
Hydroxyl initiated DNA damage is a threat to the integrity of genes, especially tumor 
suppressor genes. ROS have been implicated in various autoimmune diseases. Abnormal 
production of ROS may damage surrounding tissues and lead to diseases such as SLE. 
Systemic lupus erythematosus is a multisystem chronic, autoimmune disease 
encompassing a spectrum of diseases defined by clinical criteria. Both cell mediated and 
humoral autoreactivity precipitates SLE. One of the characteristics of SLE is a long term 
high affinity immune response to self antigens. SLE is associ.. cd with the presence of 
autoantibodies against tissue and cellular components such as DNA, RNA, cytoplasmic 
elements found in serum, phospholipids, ribonucleoproteins and histones. However, the 
main autoantibodies found in SLE are antinuclear autoantibodies that react with nuclear 
antigens such as dsDNA, ssDNA and histones. The titre of anti-DNA autoantibodies in 
SLE patients correlates with the disease activity. DNA modified with ROS, is thought to 
be involved in the development of autoantibodies in SLE. 
In the present study plasmid Bluescript DH5a"KS" DNA and native calf thymus 
DNA fragments of approximately 400 bp referred as native DNA were isolated and 
modified with hydroxyl radical, generated by the UV irradiation of hydrogen peroxide at 
254 nm. The generation of *0H radical was confirmed using mannitol, a quencher of *0H 
radical. The hydroxyl radical induced modifications referred as ROS modifications in 400 
11 
bp DNA were analysed by UV spectroscopic and thermal denaturation studies. The 
modified DNA sample showed a marked hypochromicity at 260 nm as compared to 
native DNA. The data reflects the presence of single stranded regions in the modified 
DNA. The Tm of ROS-DNA was found to be 78°C, whereas, native DNA showed a Tm 
of 88°C. A net decrease of 10°C in the Tm value of ROS-DNA indicates a partial 
destruction of its secondary structure. The single strand breaks, induced in DNA as a 
result of ROS modification were detected by nuclease SI sensitivity assay and 
hydroxyapatite column chromatography. The ROS-DNA was employed in competitive 
assay to delineate the epitope recognition of induced antibodies against ROS- plasmid 
DNA. 
The modifications in plasmid DNA were analysed by UV and fluorescence 
spectroscopic techniques. The modified plasmid DNA showed hypochromicity as 
compared to native plasmid DNA, thereby reflecting the presence of single stranded 
regions in the modified plasmid DNA. The single strand breaks induced in the plasmid 
DNA upon ROS modification were further ascertained by agarose gel electrophoresis and 
nuclease S1 sensitivity assay. 
The antigenicity of ROS-modified plasmid DNA was probed by inducing 
antibodies in rabbits. The repertoire of specificities of induced antibodies were evaluated 
by direct binding and competition ELISA. The induced antibodies exhibited 
polyspecificity, a property commonly associated with SLE anti-DNA autoantibodies. 
Anti-ROS plasmid DNA antibodies showed preferential recognition of ROS-modified 
conformers of DNA and nitrogenous bases in a competitive inhibition assay. 
A group of SLE sera with high anti-DNA antibody titre were investigated for their 
specificity towards ROS-modified and native plasmid DNA by ELISA. Direct binding 
ELISA results showed preferential binding of SLE autoantibodies to ROS-pIasmid DNA 
in comparison to native plasmid DNA. Inhibition ELISA reiterated the direct binding 
results. Gel retardation assay further substantiated the binding of native and modified 
plasmid DNA with anti-DNA antibodies. The retarded mobility of ROS-plasmid DNA 
complexed with SLE anti-DNA antibodies confirmed that the autoantibodies in SLE 
recognize the modified DNA more as compared to the native plasmid DNA. 
Ill 
Similarly, cancer sera were screened for the presence of antibodies reactive with 
native and ROS-plasmid DNA. The study consisted of 29 sera from patients with various 
types of malignancies. Direct binding ELISA showed greater recognition for ROS-
plasmid DNA as compared to the native form. Four sera from breast cancer showed 
higher recognition of ROS-plasmid DNA than native DNA. Four sera from cancer of 
head and neck also showed higher reactivity with ROS-plasmid DNA. A large group 
comprised of cancer of respiratory system, which included six sera of oral cavity and 
three sera of lung cancer. All the oral cancers showed greater reactivity with ROS-
plasmid DNA as compared to the native plasmid DNA. Whereas one out of three lung 
cancer sera showed greater binding with native plasmid DNA as compared to the 
modified form. Patients suffering from cancer of prostrate and gall bladder also showed 
higher reactivity towards ROS-plasmid DNA. Serum from vulva, Hodgkin's lymphoma 
and CML also showed higher reactivity with ROS-plasmid DNA. These studies point out 
to the fact that free radicals may contribute widely to cancer development in humans. 
In conclusion, the hydroxyl radical caused exiensive damage to plasmid DNA 
altering its immunogenicity. The antibodies against modified plasmid DNA are 
polyspecific in nature, resembling the antigen binding characteristics of SLE anti-DNA 
autoantibodies. The possibility of hydroxyl radical modified DNA in autoimmunity and 
carcinogenesis have been indicated. 
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Reactive oxygen species (ROS) are a ubiquitous part of human life having both 
beneficial and harmful effects. These are produced in cells under physiological conditions 
during the oxygen metabolism and other redox processes that are of vital importance for 
the biological function. However, excess of these radicals react v^th cellular lipids, 
proteins and nucleic acids leading to local injury and eventual organ dysfunction. 
Oxidative stress has a probable role in the pathogenesis of a variety of human diseases. 
Among ROS, hydroxyl radical is the most reactive oxidant. It is widely produced 
in many biological processes through Haber-Weiss, Fenton reactions or by ionizing 
radiations. It reacts to most biomolecules at diffusion controlled rates causing oxidative 
damage. DNA is a vulnerable and important target for *OH-induced damage causing 
destruction of bases and deoxy-ribose sugars or single or double strand breaks. The 
oxidative damage to DNA is an important factor in mutagenesis and carcinogenesis. 
Hydroxyl initiated DNA damage is a threat to the integrity of genes, especially tumor 
suppressor genes. ROS have been implicated in various autoimmune diseases. Abnormal 
production of ROS may damage surrounding tissues and lead to diseases such as SLE. 
Systemic lupus erythematosus is a multisystem chronic, autoimmune disease 
encompassing a spectrum of diseases defined by clinical criteria. Both cell mediated and 
humoral autoreactivity precipitates SLE. One of the characteristics of SLE is a long term 
high affinity immune response to self antigens. SLE is associated with the presence of 
autoantibodies against tissue and cellular components such as DNA, RNA, cytoplasmic 
elements found in serum, phospholipids, ribonucleoproteins and histones. However, the 
main autoantibodies found in SLE are antinuclear autoantibodies that react with nuclear 
antigens such as dsDNA, ssDNA and histones. The titre of anti-DNA autoantibodies in 
SLE patients correlates with the disease activity. DNA modified with ROS, is thought to 
be involved in the development of autoantibodies in SLE. 
In the present study plasmid Bluescript DH5a"KS" DNA and native calf thymus 
DNA fragments of approximately 400 bp referred as native DNA were isolated and 
modified with hydroxyl radical, generated by the UV iiradiation of hydrogen peroxide at 
254 nm. The generation of'OH radical was confinned using mamntol. a quencher of'OH 
radical. The hydroxyl radical induced modifications refeired as ROS modifications in 400 
I I 
bp DNA were analysed by UV spectroscopic and thermal denaturation studies. The 
modified DNA sample showed a marked hypochromicity at 260 nm as compared to 
native DNA. The data reflects the presence of single stranded regions in the modified 
DNA. The Tm of ROS-DNA was found to be 78°C, whereas, native DNA showed a Tm 
of 88°C. A net decrease of 10°C in the Tm value of ROS-DNA indicates a partial 
destruction of its secondary structure. The single strand breaks, induced in DNA as a 
result of ROS modification were detected by nuclease SI sensitivity assay and 
hydroxyapatite column chromatography. The ROS-DNA was employed in competitive 
assay to delineate the epitope recognition of induced antibodies against ROS- plasmid 
DNA. 
The modifications in plasmid DNA were analysed by UV and fluorescence 
spectroscopic techniques. The modified plasmid DNA showed hypochromicity as 
compared to native plasmid DNA, thereby reflecting the presence of single stranded 
regions in the modified plasmid DNA. The single strand breaks induced in the plasmid 
DNA upon ROS modification were further ascertained by agarose gel electrophoresis and 
nuclease SI sensitivity assay. 
The antigenicity of ROS-modified plasmid DNA was probed by inducing 
antibodies in rabbits. The repertoire of specificities of induced antibodies were evaluated 
by direct binding and competition ELISA. The induced antibodies exhibited 
polyspecificity, a property commonly associated with SLE anti-DNA autoantibodies. 
Anti-ROS plasmid DNA antibodies showed preferential recognition of ROS-modified 
conformers of DNA and nitrogenous bases in a competitive inhibition assay. 
A group of SLE sera with high anti-DNA antibody titre were investigated for their 
specificity towards ROS-modified and native plasmid DNA by ELISA. Direct binding 
ELISA results showed preferential binding of SLE autoantibodies to ROS-plasmid DNA 
in comparison to native plasmid DNA. Inhibition ELISA reiterated the direct binding 
results. Gel retardation assay further substantiated the binding of native and modified 
plasmid DNA with anti-DNA antibodies. The retarded mobility of ROS-plasmid DNA 
complexed with SLE anti-DNA antibodies confirmed that the autoantibodies in SLE 
recognize the modified DNA more as compared to the native plasmid DNA. 
i n 
Similarly, cancer sera were screened for the presence of antibodies reactive with 
native and ROS-plasmid DNA. The study consisted of 29 sera from patients with various 
types of malignancies. Direct binding ELISA showed greater recognition for ROS-
plasmid DNA as compared to the native form. Four sera from breast cancer showed 
higher recognition of ROS-plasmid DNA than native DNA. Four sera from cancer of 
head and neck also showed higher reactivity with ROS-plasmid DNA. A large group 
comprised of cancer of respiratory system, which included six sera of oral cavity and 
three sera of lung cancer. All the oral cancers showed greater reactivity with ROS-
plasmid DNA as compared to the native plasmid DNA. Whereas one out of three lung 
cancer sera showed greater binding with native plasmid DNA as compared to the 
modified form. Patients suffering from cancer of prostrate and gall bladder also showed 
higher reactivity towards ROS-plasmid DNA. Serum from vulva, Hodgkin's lymphoma 
and CML also showed higher reactivity with ROS-plasmid DNA. These studies point out 
to the fact that free radicals may contribute widely to cancer development in humans. 
In conclusion, the hydroxyl radical caused extensive damage to plasmid DNA 
altering its immvmogenicity. The antibodies against modified plasmid DNA are 
polyspecific in nature, resembling the antigen binding characteristics of SLE anti-DNA 
autoantibodies. The possibility of hydroxyl radical modified DNA in autoimmunity and 
carcinogenesis have been indicated. 
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In 1953, British physicist turned biologist Francis Crick and American biochemist 
James Watson determined the structure of DNA, forever changing the study of genetics, 
and inadvertently creating the new field of molecular biology. The helical structure as 
described by Watson and Crick, called B-DNA, is only one of the several possible 
conformations. Other DNA conformations although having the same nucleotides and 
molecular bonds, exhibit different three-dimensional helical structure. At least six 
different DNA conformations have been identified (designated as A, B, C, D, E and Z), 
but only the A, Z and B conformation are found in nature (Adams et al, 1981; Rich el 
al, 1984; Pechenaya, 1993). B-DNA is the most common form of DNA found in living 
organisms. Z-DNA is so called because phosphate groups in the backbone are zig-zagged 
(Rich et al, 1984). Besides, the double helical structure, DNA can adopt many more 
different conformations or structures (Rich et al., 1984). Triple stranded nucleic acids and 
quadruple - stranded nucleic acids have also been found in DNA (Felsenfeld et al, 1957; 
Rich, 1958). The different conformations adopted by DNA reflect its enormous 
versatility that is inherent in the molecule. 
Essential Features of Bacterial Plasmids 
Plasmids are extrachromosomal genetic elements frequently found in bacteria. 
They are circular and range in size from I kb to 200 kb. They usually contain several 
genes including those encoding antibiotic resistance. Each has an origin of replication. 
They are transmitted from bacteria to bacteria by conjugation or by transformation. 
The Bluescript SK (-) phagemid excised from the lambda ZAP vector with helper 
phage, is a 2958 base pair multipurpose phagemid vector designed for rapid sequence 
analysis. The polylinker within the lambda ZAP contains twenty one restriction sites, six 
of which are unique in the lambda vector. The vector also has an insert capacity of upto 
10 kb without exceeding the packaging limit, which is 105% of wild type lambda phage. 
This large capacity in addition to the choice of cloning sites and in vivo excision process 
makes the lambda ZAP vector attractive for the construction of genomic libraries. 
Antigenicity of DNA 
DNA is a complex macromolecule whose biological role encompasses both 
immune regulation and heredity. DNA can exert powerful effects that lead to immune 
system activation as well as antibody production. The immimological activity of DNA is 
especially surprising, because for many years, DNA was considered as an 
immunologically blunt and inert molecule whose information content and functions were 
solely genetic. The antigenic properties of nucleic acids was recognised when native 
DNA was identified to bind systemic lupus erythematosus autoantibodies (Cepellini et 
al, 1957; Meischcr and Strassie 1957; Robbins et al, 1957). 
Until the last decade, the immune properties of DNA were studied almost 
exclusively in relation to SLE. Because of the central role of anti-DNA in SLE, 
investigators attempted to mimic this disease in animals by immunization with DNA 
(Messina e/at/., 1993). In general, these efforts were unsuccessful. Although 
immunization with single stranded (ss) DNA can elicit a limited antibody response, 
mammalian double stranded (ds) DNA, even when complexed with a protein carrier and 
administered in adjuvant, fails to induce an appreciable response to dsDNA, the 
serological hallmark of SLE (Madaio et al, 1984). However, conformations of DNA 
other than the native form (B-form) such as the left handed Z-DNA, (Lafer et al, 1981; 
Madaio et al, 1984), DNA modified with drugs, hormones, free radicals (Moinuddin and 
Ali 1994; Ara and Ali, 1995; Arjumand et al, 1995; Ashok and Ali, 1998; Cooke et al, 
1997) and certain synthetic nucleic acid polymers like poly(dT), poly(dC), poly(dA), 
poly(dl) and poly(G) can induce antibodies that react selectively with the immunogen 
(Stollar, 1986; Braun and Lee, 1988; Garg and Ali, 1998). 
Modified DNA by chemical or physical means as well as helical structures that 
differ significantly from B-DNA are much stronger immunologic stimuli than nDNA and 
most of the antibodies induced by modified nDNA do not react with the unmodified 
DNA (Anderson et al, 1988). The biological effects of DNA in the case of immune 
stimulation results from both sequence and backbone (Pisetsky, 2000). 
Bacterial DNA in contrast to mammalian DNA, induces a variety of responses in 
both normal humans and animals (Pisetskey, 1997). The differences between bacterial 
DNA and mammalian DNA have been examined as clues to DNA immimogenicity 
(Gilkeson et ai, 1989). Bacterial DNA contains sequence or conformations rarely found 
in mammalian DNA and these sequences render it immunogenic. Low molecular weight 
DNA found in DNA-anti-DNA complexes of lupus patients is enriched in CG content 
(Sano et ai, 1983). The CG rich DNA region has the tendency to form Z-DNA, which is 
highly immunogenic. Alternatively, CG enriched DNA could act as a mitogen. A 
relationship between GC content and mitogenic potential has been suggested (Messina el 
ai, 1993). The immunological effects of DNA can influence the pathogenesis of many 
infectious and autoimmune diseases. 
Antigenicity of Plasmid DNA 
DNA immunization elicits strong immunity to many infectious pathogens 
including parasites, bacteria and viruses (Whalen, 1996; Ulmer et ai, 1996). Several 
groups have reported that the injection of plasmid DNA carrying cDNA expression 
cassettes results in expression of the encoded proteins in vivo with the concomitant 
development of cellular and humoral immune responses directed against the encoded 
antigens (McDonnell, 1996). 
The immunogenicity of plasmid DNA requires short immunostimulatory DNA 
sequences (ISS) that contain a CpG dinucleotide in a particular base content (Krieg et al, 
1995, Sato et al., 1996, Grifantini et ai, 1998). The ISS include the following CpG 
containing hexamer 5 ' - GACGTC - 3', 5 ' - AGCGTC - 3' and 5 ' - AACGTT - 3' 
(Yamamoto et al., 1992; Yamamoto et al., 1994). The CpG motifs of bacterial - derived 
plasmids augment antigen - specific immune responses and steer those responses towards 
the T helper 1 type, leading to the inducement of IgG2a and interferon y expression and 
to the suppression of immunoglobulin E (IgE) synthesis (Roman et al, 1997; Chu et al, 
1997). The immunostimulatory function of their CpG motifs probably resulted from the 
secretion of various cytokines, such as interleukin 12 (IL-12), IFN-y, tumor necrosis 
factor (TNF)-a and IL-6, from macrophages or natural killer (NK) cells in the local 
enviroimient (Klinman et al., 1996; Roman et ai, 1997). 
Furthermore prokaryotic DNA contains frequent methylated adenosine residue, 
which may promote regions of imique conformations. These methylated bases are much 
less abundant in mammalian DNA (Doefler, 1983). Mammalian DNA, in contrast 
contains methylated C in CpG doublets to much greater extent than bacterial DNA. This 
is especially relevant because the poly (CG) with methylated C is much less mitogenic 
than poly (CG) with unmethyfated C (Messina et al., 1993). CpG containing 
oligonucleotides were found to be stimulatory and that stimulation was eliminated by the 
methylation of the C or substitution for either the C or the G (Krieg et al., 1995; Sato el 
al., 1996). Therefore, uimiethylated CpG sequences are especially mitogenic and 
immunogenic. Reduced methylation of the C's in CpG's either due to failure to methylate 
C's in certain genes or due to demethylation of CpG's as a result of gene activation, 
results in generation of immunogenic DNA in SLE. 
Plasmid DNA can be divided conceptually into two distinct units: a transcription 
unit that directs antigen synthesis and an adjuvant unit in the plasmid backbone that 
elicits the production of type 1 IFN and IL-112 in transfected skin keratinocytes and 
antigen presenting cells. Hence manipulation of the transcription imit to yield higher 
levels of antigen expression does not necessarily produce stronger immune response. 
Both the localization and the precise sequence of the ISS within the plasmid backbone are 
also important for DNA vaccination (Sato et al., 1996). 
DNA immunization technology is a very promising approach to the formulation 
of multivalent vaccines (Grifantini et al., 1998). Purified plasmid DNA containing an 
antigen's coding sequences and the necessary regulatory elements to express them is 
introduced into the tissue. The effectiveness of DNA vaccines against viruses, parasites 
and cancer cells has been demonstrated in numerous animal models. DNA vaccine 
research is providing new insights into some of the basic immunological mechanism of 
vaccination such as antigen presentation, the role of effector cells and immunoregulatory 
factors (Mor and Eliza, 2001). Multiepitope DNA vaccines can be engineered to enhance 
CTL immunogenicity by increasing processing efficiency (Livingston et al., 2001). 
Epstein Ban Virus (EBV) based plasmid vectors may greatly contribute to 
nonviral gene therapy against a variety of disorders, including malignant, congenital 
chronic and infectious diseases. These vectors contain EBNA 1 gene and Ori P element 
that enables high transfer efficiency, strong transgene expression and long term 
maintenance of the expression (Mazda, 2002). DNA vaccines can activate immunity 
against tumor antigens expressed as MHC class I associated peptides. However priming 
of CDg4 CTL against weak tumor antigen may require adjuvant molecules (Rice et al., 
2002). 
Despite an abundance of preclinical data, relatively little is known regarding the 
efficiency of DNA vaccination of humans. Conry et al (2002) have conducted dose 
escalation clinical trial of a dual expression plasmid encoding carcinoembryonic antigen 
(CEA) and hepatitis B surface antigen (HBSAg) in patients with metastatic colorectal 
carcinoma. This pivot trial has provided encouraging human immune response data in 
support of this vaccine technology. 
Free Radicals 
Free radicals are chemical species that possess an unpaired electron in the outer 
shell of the molecule. These are highly reactive (Halliwell and Gutteridge, 1989) and 
have extremely short half lives. They quickly react with other compounds, trying to 
capture the needed electron to gain stability. Generally free radical attack the nearest 
stable molecule, stealing its electron. When the attacked molecule loses its electron, it 
becomes a free radical itself, beginning a chain reaction. Once the process is started it can 
cascade, finally resulting in the disruption of a living cell. 
Free radicals are produced continuously in cells either as byproducts of 
metabolism or deliberately as in phagocytosis (Cheeseman and Slater, 1993). Some free 
radicals arise normally during metabolism. Sometimes the body's immune systems cells 
create them to neutralize viruses and bacteria. However, environmental factors such as 
pollution, radiation, cigarette smoke and herbicides can also spawn free radicals. Table 1 
lists some sources of oxidative stress. 
TABLE -1 
Source of oxidative stress in human pathophysiology 
Source Mechanism 
Mitochondrial electron transport 
Transition Metal ions 
Inflammation 
Enzymes e.g. xanthine oxidase 
Drug metabolism e.g. paracetamol 
Cigarette smoke 
Radiation 
Leakage of superoxide due to inefficient 
reduction of O2 
Cu and Fe facilitate hydroxyl radical 
formation 
Free radicals released by activated 
phagocytes 
Release superoxide during reperfiision of 
ischemic tissue 
Free radical intermediate created during 
metabolism 
Gas phase rich in free radicals 
X rays, UV light 
Free radicals can be generated both in vivo and in vitro by one of the following 
mechanisms: 
1. Homolytic cleavage of a covalent bond, in which a normal molecule fragments in 
two, each fragment retaining one of the paired electrons (Von Sormtag, 1987). 
Homolytic cleavage occurs less commonly in biological systems, as it requires high 
energy input from ulfra violet light, heat or ionizing radiation. 
2. Loss of single electron from a normal molecule. 
3. Addition of electron to a normal molecule. 
Free radicals can be negatively charged, positively charged or electrically neutral 
(Cheeseman and Slater, 1993). The most important free radicals in the body are the 
radical derivates of oxygen better known as reactive oxygen species. These include 
oxygen in its triplet state (^62) or singlet state ('O2), superoxide anion (OD, hydroxy! 
radical (OH), nitric oxide (NO), peroxynitrite (ONOO), hypochlorous (HOCl), 
hydrogen peroxide (H2O2), alkoxyl radical (LO), and the peroxyl radical (LO2). 
(a) Superoxide 
The superoxide free radical anion is formed when oxygen is reduced by the 
transfer of a single elecfron to its outer shells (Florence, 1990; Harris, 1992). The major 
source of superoxide in vivo is the electron leakage that results from the electron transfer 
chain of the mitochondria. Superoxide on its own isn't particularly damaging. However, 
the superoxide radical anion appears to play a central role as other reactive intermediates 
are formed from it. Its main significance is probably as a source of hydrogen peroxide 
and as a reductant of transition metals, which are precursors to the formation of the lethal 
hydroxyl radical (Halliwell and Gutteridge, 1992). Its reaction with NO, which is 
believed to be the identity of endothelium derived relaxing factor, may also prove to be 
physiologically important. 
(b) Hydrogen Peroxide 
Hydrogen peroxide is not a free radical but falls in the category of ROS and is the 
most extensively studied oxygen metabolite (Harris, 1992). 
Hydrogen peroxide can be generated from the two electron reduction of oxygen. 
In biological systems, dismutation of superoxide by superoxide dismutase is the major 
source of H2O2 (Tachon, 1989). 
20*2"+ 2H^ ^Q^ ) H2O2 + O2 
It is an oxidizing agent that is not particularly reactive but its main significance 
lies in that it is the main source of hydroxyl radicals in the presence of transition metal 
ions (Aruoma and Halliwell, 1987; Aruoma et ai, 1991). 
H2O2 induces a broad spectrum of responses in mammalian cells (Davies, 1999), 
primarily DNA strand breaks (Cantoni and Giacomoni, 1997). Protein kinases and 
phosphatases, proteins containing sulfhydryl group and lipids are also among the 
potential targets (Abe et al., 1996; Hirpara and Clement, 2001). H2O2 may induce both 
apoptosis and necrosis (Chandra et al., 2000; Antunes and Cadenas 2001; Yang et ai, 
2001). However recent studies show that H2O2 can also exert anti-apoptotic actions 
(Barboutiera/., 2002). 
(c) Hydroxyl Radical 
Hydroxyl radical is a highly reactive and toxic radical with one unpaired electron. 
It is formed through one electron reduction of hydrogen peroxide (Koppenaol and 
Liebman, 1984). It is highly electrophillic in nature (Imamura and Hirao, 1979). Thus it is 
a powerful oxidizing agent. It is formed in living cells during physiological processes or 
after environmental stimulation. Since it's a highly reactive radical, once it is formed, it 
will react with various biomolecules. This then causes different biological damage 
eventually leading to many disease states. The 'OH readily reacts wdth a variety of 
biological macromolecules including DNA, protein, membrane lipids and cause DNA-
protein crosslinks (Von Sonntag, 1987 a,b; Dizdaroglu 1991; Halliwell and Aruoma, 
1991). It reacts with DNA by abstracting a hydrogen atom from the deoxyribose sugars 
along the DNA backbone thus causing strand breaks. Mounting evidence suggests that 
hydroxyl radicals give rise to mutagenic base lesions in DNA, such as 8-oxo-guanine 
(Cheng et al., 1992; Feig and Loeb 1993; Feig et al., 1994) and 8-oxo-adenine (Kamiya 
etai, 1995). 
Generation of Hydroxyl Radical 
Hydroxyl radical is generated in a number of ways. The first is their generation by 
the decomposition of H2O2 via the Fenton reaction (Fenton, 1894). 
Fe^^ + H2O2 • Fe^^ + 'OH + 0H~ 
Interaction of superoxide with H2O2 through the Haber-Weiss reaction (Haber and Weiss, 
1934) also leads to the generation of'OH. 
2 0 r + H2O2 > O2 + H2O + 'OH 
When water is exposed to ionizing radiations, such as x-ray and y-ray, hydroxyl radical is 
produced (Von Sonntag 1987C). Cell killing caused by ionizing radiation is mostly due to 
the hydroxyl radicals produced by water radiolysis (Baxton et al, 1988). 
H2O — ^ H20'^ + e-aq 
H^O'^  + HzO ^^'"y^^'^ ) HBO^ + ' O H 
Photolysis is another important way to produce hydroxyl radical. UVB (280-320 
nm) is responsible for this reaction UV can directly split H2O2 into two *0H (Masaki et 
al, 1995). 
H2O2 " ^ > 'OH + 'OH 
Hydroxyl radicals can also be generated when the reduced forms of transition 
metal ions such as copper or chromium combine with H2O2. 
Cu^ + H2O2 • Cu^^ + 'OH + OH" 
Hydroxyl radical was also detected when H2O2 reacted with nitric oxide in the 
absence of transition metals. Recent studies have shown that tetra chlorohydroquinon and 
hydrogen peroxide complex also has the ability to generate hydroxyl radical in a metal -
independent way (Zhu et al, 2000). 
Hydroxyl Radical in Cell Function 
Activated neutrophils release hypochlorous acid (HOCl) and O^, which in turn 
forms hydroxyl radical. This is due to the cytotoxic effects of the neutrophils (Umeda et 
al, 1985). NADH, GSH and H2O2 are involved in respiration, it is reported that GSH and 
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NADH can react with H2O2 to produce hydroxyl radical, which has considerable 
biological significance (Florence, 1984). 
Reactive oxygen species (ROS), such as hydrogen peroxide, superoxide and 
hydroxyl radicals are products of oxygen metabolism in all aerobic organisms. ROS are 
generated as a result of energy production from mitochondria (from the electron transport 
chain) (Fiskum, 2000), as a part of antimicrobial (Weiss and Lo Buglio, 1982) or antiviral 
(Griot et al, 1989) response, as well as the detoxification reactions carried out by the 
cytochrome P-450 system (Cederbaum, 1989; Scholz et al, 1990). Environmental agents 
such as ultraviolet light, ionizing radiation, redox chemicals and cigarette smoke also 
readily generate ROS. Oxidative stress occurs when the production of ROS exceeds the 
body's natural antioxidant defense mechanisms, causing damage to biomolecules such as 
lipids, proteins and DNA. Indeed, oxidative DNA damage has been implicated as the 
cause of some forms of cancer (Ames, 1989). ROS such as 'OH and H2O2, produced by 
inflammatory cells have been proposed to contribute multistage carcinogenesis by 
inducing DNA or tissue damage in inflammed tissues (Ames et al., 1993). 
Spectrum of DNA Damage Resulting from Oxidative Stress 
Oxidative damage to DNA is a result of interaction of DNA with ROS, in 
particular the hydroxyl radical. Superoxide and hydrogen peroxide are normally not 
reactive towards DNA. However, in the presence of ferrous or cuprous ions (the Fenton 
reaction), both superoxide and hydrogen peroxide are converted to the highly reactive 
hydroxyl radical. Hydroxyl radical produces a multiplicity of modifications in DNA 
(Dizdaroglu, 1992). They can be divided into three groups including damage of bases, 
damage of deoxyribose and the appearance of new covalent bonds (cross linking). 
Pyrimidines are very susceptible to oxidation at the C5-C6 position. Hydroxyl 
radical adds to the C5 and C6 positions of thymine and cytosine, generating C5-0H and 
C6-OH adduct radicals, respectively (Dizdaroglu et al, 2002). Oxidation reactions of the 
C5-0H adduct radicals of cytosine and thymine followed by addition of *0H leads to the 
formation of cytosine and thymine glycols (Von Sonntag, 1987; Dizdaroglu, 1992; Breen 
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and Murphy, 1995). Cytosine glycols can be deaminated forming uracil derivatives that 
preferentially form base pair with adenine, thus substituting A:T for C:G. 
Oxidation of purines often results in cleavage of the pyrimidine-coupled 
imidazole ring forming formamidopyrimidine residues (Fapy) (Dizdaroglu, 1992). 
8-oxoguanine (8-oxoG) and its tautomeric form, 8-hydroxyguanosine attract significant 
attention among the products of purine oxidation. 8-oxoG is considered as an indication 
of oxidative stress (Shigenaga et al, 1989). Oxygen radicals can induce deamination of 
guanine and adenine resulting in the appearance of xanthine and hypoxanthine in DNA 
with concomitant significant mutagenic defects (Nguyen et al., 1992). 
Deoxyribose is attacked by ROS in positions CI forming the base-fi-ee region (AP 
site) and C4 resulting in fragmentation of deoxyribose (Dizdaroglu et al., 1977; Beesk et 
al., 1979). Hydroxyl radical reacts with the sugar moiety of DNA by abstracting an H-
atom from each of the carbon atoms generating various sugar products, DNA strand 
breaks and base-free sites (Von Sonntag, 1987). 
DNA-protein cross links are also formed by free radical reactions (Distel and 
Schussler, 1996). A thymine-tyrosine cross-link was identified in mammalian chromatin 
in vitro and in cells exposed to free radical-generating systems (Dizdaroglu, 1992; 
Olinski et al., 1992; Altman era/., 1995; Toyokunie/a/., 1995; Carlton e/a/., 1999). 
Consequences of various types of oxidative damage are different. For example, 
thymine glycols and Fapy block replication (Boiteux and Laval, 1983; Basu et al., 1989); 
they are cytotoxic but their mutagenic potential is limited. In contrast 8-oxoG is highly 
mutagenic when present in matrix because all replicative DNA-polymerases insert dAMP 
as the complementary residue, thus substituting T:A for G:C (Shibutani et al., 1991). 
ROS can directly induce single strand breaks of DNA cleaving the sugar-phosphate bond 
(Peskin, 1997). Transition metal ions are very important for oxidative damage of DNA 
(Luo et al., 1996; Henle et al., 1996). ROS can alter ion homeostasis (Nicotera et al.. 
1990) and induce Ca^ ^ release from mitochondria (Richter and Frei, 1988) that results in 
activation of nucleases (Jones et al., 1989). 
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Fig. 1. Main branches of cellular response to DNA damage. 
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Repair of Oxidative Modification of DNA 
A number of oxidative alterations of DNA are virtually dangerous because they 
can block replication and transcription by nucleotide substitutions. In order to maintain 
the fidelity of genetic material all organisms have evolved many different repair 
pathways to remove various types of DNA damage. Oxidative damage is repaired by a 
ubiquitous base excision repair pathway (Kow et ai, 1991; Kow, 1994). Glycosylases 
and endo and exonucleases remove the oxidized damaged sites. E.coli enzymes have 
been studied in great detail, some data obtained in eukaryotes appear significant. The 
repair of DNA sites carrying the nucleotide normally begins independently from its 
oxidative origin. Endonuclease III works not only with thymine glycol and 
dihydrothymine, but also with various pyrimidine derivatives, with unsaturated C5-C6 
bond and wdth fragmented bases (Boorstein et ai, 1989). In mammalian cells, there are 
UV-endonucleases I and II that are similar to endonuclease III (Kim and Linn, 1989). 
Similar enzymes were detected in mitochondria (Tomkinson et al, 1990) indicating that 
mitochondrial DNA is repaired (Driggers et cr/., 1993). Oxidative damage of 
mitochondrial DNA is at least 100 folds higher than that of nuclear DNA (Shigenaga el 
al, 1994). Nucleotide substitutions of mitochondrial DNA are the cause of various 
serious diseases (Hao and Moraes, 1996). 
Non-methylated formamide-pyrimidine derivatives of adenine and guanine are 
removed by formamide-pyrimidine glycosylase (in E.coli this enzyme is Fpg/Mut M) 
(Cabrera et al, 1988). This enzyme is also active towards 8-oxoG (Tchou et al, 1991). 
Bacterial Mut Y protein removes adenine from the pair 8-oxoG:A (Michaels et al, 1992). 
The Mut T protein eliminates 8-oxoG from the nucleotide pool and prevents its 
incorporation into DNA instead of dATP. HmtHl protein is the human variant of this 
enzyme (Okamoto et al, 1996). 
The highly specialized enzyme uracil DNA glycosylase recognizes oxidative 
modification of cytosine in DNA (Dizdaroglu et al, 1996). Enzymes combining 
phosphodiesterase and phosphomononuclease activities initiate repair of oxidized AP 
sites and fragmented deoxyribose induced by ROS. In E.coli this fimction is performed 
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by exonuclease III. In mammalian cells, there is an Ape protein homologous to 
exonuclease III, it is also called Hap I, Bap I, Apex or Ref 1. Unlike the bacterial protein, 
it restores the DNA binding of the AP-1 transcription factor lost upon oxidation 
(Xanthondakis,e^a/., 1992). 
Exposure to O2 (Chan and Weiss, 1987) and NO (Nunoshiba et a/., 1993) 
increases the content of endonuclease IV. This enzyme possess DNA-specific 3-
phosphatase activity, thus generating a free 3'-0H-end required for repair DNA 
polymerases. 
Excision repair enzymes are required to remove large changes in DNA including 
covalent bonds with molecular-weight hydrocarbons and formation of pyrimidine dimers 
(T-T, T-C, C-C). These alterations are identified by large multienzyme complexes which 
detect large changes, cleave phosphodiester bonds at both ends and remove a 12 or 13 
base oligonucleotide. In E.coli. the mechanism includes UvrA, UvrB, and UvrC proteins. 
(Sancar and Sancar, 1988). The system can excise thymine glycols, AP sites and 8-oxoG 
(Maki and Sekiguchi, 1992). 
Antioxidants 
Antioxidants are molecules which can safely interact with free radicals and 
terminate the chain reaction before vital biomolecules like proteins, nucleic acids, 
phospholipids and sugars are damaged. Aerobic organisms have potent antioxidant 
defences, these may be primary or secondary. The defences that directly decompose or 
and scavenge H2O2 and *OH are known as primary defences. While secondary 
antioxidant defences consist of the repair mechanisms that act on biomolecules that have 
imdergone oxidative damage. 
Interest in the use of antioxidants for the treatment of human disease, and in the 
role of dietary antioxidants in the prevention of disease development, has been sustained 
for the last two decades. The production of ROS as a consequence of aerobic metabolism, 
can damage proteins, lipids and DNA. To abate the deleterious effects of ROS, cells 
employ defensive enzymes such as superoxide dismutase (SOD), catalase and glutathione 
peroxidase (Ballmer et al, 1994). Table 2 summarizes the role of these antioxidant 
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defences in neutralizing and minimizing the potentially cytotoxic effects of reactive 
oxidants. 
Although there are several enzyme systems within the body that scavenge free 
radicals, the principle micronutrients (vitamin) oxidants are vitamin E, P-carotene and 
vitamin C. Fruit and vegetable consumption decreases the amount of free radical damage 
to DNA in the human body thereby reducing the chances of getting cancer (Ames et al., 
1993). 
Vitamin E is the major lipid soluble antioxidant found in cells. The effects of 
inadequate vitamin E intake usually develops over a long time, typically decades and 
have been linked to chronic diseases such as cancer (Trickier and Shklar, 1987; Knekt, 
1988) and cardiovascular disease (Stephens et al., 1996). Its main function is to prevent 
the peroxidation of membrane phospholipids thus preventing cell membrane damage 
through its antioxidant action (Niki et al., 1988). Vitamin E also stimulates the immune 
response. Lowered interleukin-2 production and altered prostaglandin synthesis (Meydani 
et al., 1986) is seen in vitamin E deficiency. 
Vitamin C acts as an antioxidant by scavenging potentially damaging oxygen free 
radicals (Cooke et al., 1998). Intakes of vitamin C below the recommended daily 
allowance are associated with increased free radical damage to DNA (Rehman et al.. 
1998; Fraga et al., 1996). It has been shown that vitamin C supplementation has 
significant influence upon DNA, serum and urinary 8-oxodG levels and stimulates the 
repair of 8-oxodG in DNA pool (Cooke et al., 1998). 
Many carotenoids including p-carotene, can be metabolized to vitamin A 
(retinol). The antioxidant activity of carotenoids is thought to be particularly directed 
against O2 (Palozza and Krinsky, 1992; Sies et al., 1992; Bertam 1993; Krinsky 1993). 
Additionally, selenium, a trace metal that is required for proper fimction of one of 
the body's antioxidant enzyme systems, acts as a protective agent against the toxic effect 
of hydroperoxides. Low levels of selenium have been implicated in carcinogenesis 
(Combs, 1985). Studies on metalloporphyrins show a broad range of antioxidant 
activities leading to dismutation of superoxide (Day et al., 1995), hydrogen peroxide 
(Day et al., 1997) and scavenging of peroxynitrite (Szabo et al., 1996). Oxidative damage 
TABLE - 2 
Classification of major antioxidants 
Antioxidant Role Remark 
1. Enzymes Superoxide 
dismutase (SOD) 
mitochondrial 
cytoplasmic 
extracellular 
Catalase 
Dismutates O2 to H2O2 
Dismutates H2O2 to H2O 
Glutathione Removes H2O2 and lipid 
peroxidase (GSH.Px) peroxides 
Contains manganese 
Contains copper and zinc 
Contains copper 
Tetrameric hemoprotein 
present in peroxisomes 
Selenoproteins Primarily 
in the cytosol, also 
mitochondria uses GSH) 
2. Vitamins Alpha tocopherol 
Beta-carotene 
Breaks lipid peroxidation, Fat soluble vitamin 
lipid peroxide, 0*2" and 'OH 
scavenger 
Scavenges *0H, O2" and 
peroxy radicals. 
Prevents oxidation of 
Vitamin A. 
Binds to transition metals 
Fat soluble vitamin 
Ascorbic acid Directly scavenges 'OH O2 
and H2O2. 
Neutralizes oxidants from 
stimulated neutrophils. 
Contributes to regeneration 
of Vitamin E 
Water soluble vitamin 
Modified from Heffher and Repine (1989) Am. Rev. Respir. Dis. 140: 531-554. 
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to DNA is most evident in the mitochondrial genome. The antioxidant role of 
metalloporphyrin is seen in hydrogen peroxide induced mitochondrial DNA damage 
(Milano and Day, 2000). The thiol-containing nucleophile, N-acetylcysteine (NAC) is 
capable of detoxifying electrophiles and free radicals that are implicated in cancer and 
other diseases (De Flora, 1995). Recently the antigenotoxic and anticarcinogenic 
properties of NAC are being investigated (Malins et al, 2002). 
Oxidative stress occurs when the production of ROS exceeds the body's natural 
antioxidant defense mechanism, causing damage to biomoiecuies such as lij^ids, proteins 
and DNA. Oxidative stress has been thought to contribute to the general decline in 
cellular functions that are associated with many autoimmune diseases (Calabrese et al., 
1994; Miyata et al., 1998; Evans et al., 2000) and human cancers (De Weese et al, 1998; 
Meyer era/., 1998). 
Autoimmunity 
Autoimmvmity is a state wherein the host mounts an immune response to self 
Autoimmune state includes four possible permutations. 
1. The antiidiotypic responses normal hosts mount in order to modulate normal 
antibody responses, as might occur following an acute infection (Shoenfeld. 
1996). 
2. The immune response to transformed cells that occur in patients suffering from 
malignancies or from intracellular infections (Shoenfeld, 1996). 
3. The detrimental autoimmune response in the abnormal host exemplified by the 
paraneoplastic syndrome (Lemmark, 1997). The immune response to malignant 
cells cross reacts with normal tissue antigens causing an autoimmime disorder. 
4. The immime response in an otherwise normal host which results in a classic 
autoimmune, clinico-pathologic condition such as lupus, diabetes or thyroiditis. 
Autoreactivity appears to be a normal house keeping process within our immune 
system. It appears that T lymphocytes mature in thymus. Self peptides in the context of 
self-MHC are presented by thymic cells to immature T lymphocytes flowing through the 
developing thymus. Immature T lymphocytes engage these complexes via their T cell 
receptors (TCR). T cells which fail to recognize any complexes or which bind with high 
affinity/avidity are allowed to undergo apoptosis (negative selection) (Aston-Rickardt 
and Tonegawa, 1994; Nossal, 1994; Von Boehmer, 1994). T cells with lower affinity 
binding survive, exit the thymus and enter the peripheral circulation (positive selection). 
Through these and other editing processes a state of self tolerance is achieved (Goodnow, 
1992). 
The mechanisms responsible for the transition from normal autoimmunity to 
autoimmune disease states are unknown. Epitope spreading, idiotypic network 
dysregulation and defective apoptosis (Moimt and Zhou, 2001) are few of the recent 
causes of autoimmime diseases. Delayed clearance of apoptotic cells is also a factor in 
the development of SLE. The major factors associated with the development of 
autoimmunity are genetic, immunologic, hormonal and environmental (Brickman and 
Shoenfeld, 2001). Twin studies in lupus and in RA (Criswell and Amos, 2000) as well as 
multiplex family studies involving lupus and diabetic (Craddock et al, 1998; Harley et 
al, 2001) patients prove that autoimmune diseases are both muUigenic and muUifactoriai 
in etiology. 
Majority of genes which have been associated with autoimmune diseases map 
within the MHC of man, or HLA region. The HLA molecules present on the surface of 
all nucleated cells are encoded for within the major histocompatibility complex on the 
short arm of chromosome 6 in humans (Klein and Sato, 2000). The HLA genes function 
as secondary genes to allow expression of specific autoimmunity. Most of the MHC 
association with SLE, the prototype of autoimmune diseases, involves class II (HLA-DR 
and DQ alleles) and class III alleles especially null or deficiency alleles of the fourth 
component (C4) of complement (Bias et al, 1986; Goldstein and Amett, 1987; Braun and 
Zachary, 1988; Amett and Moulds, 1991; Deodhar, 1992). Multiple hypothesis have been 
presented to explain how particular HLA alleles confer susceptibility to particular 
diseases (Brickman and Shoenfeld, 2001). Errors in HLA-peptide T lymphocyte selection 
in the thymus, in HLA molecules folding or in peripheral APC presentation of antigens in 
the context of particular HLA proteins have been proposed (Colbert, 2000). 
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Hormones are a significant factor in the development of autoimmune disorder 
(Ahmed and Talal, 1999; Lahita, 1999). Autoimmune diseases occur far more commonly 
in females than in males, with a ratio of 10:1 or greater in certain diseases. Hormonal 
factors such as sex hormones, thymic hormones and corticosteroids play a significant role 
(Talal, 1989; Counihan et al, 1991; Lahita 1992; Moinuddin and Ali, 1994). Additional 
hormones including DHEA (Van Vollenhoven et al., 1998), progesterone (Van 
Vollenhoven and Mc Giure, 1994) and prolactin (Walker et al, 1998) appear to have 
immuno-regulatory properties. Their role in autoimmune diseases is presently under 
investigation. 
Autoimmunity may be antibody or cell mediated or a combination of both. In the 
case of antibodies, B lymphocytes, although possessing receptors for self antigens e.g. 
thyroglobulins, DNA, IgG do not normally produce significant quantities of antibodies 
unless they receive T cell help. This will not, in health, be given, because T cells with 
high affinity for self determinants will have undergone apoptosis in thymus (Aston-
Rickardt and Tonegawa, 1994; Nossal, 1994; Von Boehmer, 1994). However if antigen is 
presented in slightly altered form, or way, e.g. chemically altered or with upregulated 
MHC class II, then helper T cells may be activated. The activated T cells can lead to 
tissue destruction either by direct killing or by activating macrophages and a potent 
inflammatory response (Lorenz et al., 2001). T cells have been implicated as the likely 
primary mediator of several autoimmune diseases including rheumatoid arthritis, multiple 
sclerosis and type I insulin dependent diabetes mellitus. In a wide variety of autoimmune 
diseases like SLE, Sjogren's syndrome, progressive systemic sclerosis, rheumatoid 
arthritis and pernicious anaemia, the regulatory failure results in a significant decrease in 
T suppressor cell numbers and activity, thereby unbalancing the T-helper/T-suppressor 
cell ratio (Krakauer et al, 1981). 
B cells play a paramount role in systemic autoimmunity (Zouali, 2001). B cell 
receptor signaling requires a tight regulation of several protein tyrosine kinases and 
phosphatases. Altered or abnormal signaling results in production of pathogenic 
autoantibodies and lupus like glomerulonephritis (Huck et al, 2001). Altered expression 
of signaling molecules in T and B lymphocytes from patients with human lupus suggests 
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that the subversion of signaUng could account for the hyperproduction of autoantibodies 
(Zouali, 2002). Human B cell hybridomas were established to define new autoantigens of 
importance for autoimmune diseases such as rheumatoid arthritis and SLE. Antibodies 
against a particular epitope localized within human light chains have been detected in 
patients of SLE (Von Landenberg et al, 1999). 
Environmental factors have been implicated in autoimmune diseases. These 
include viruses, infectious agents, medications, (Aharon Maor and Shoenfeld, 1998; 
Saraux et al., 1999). While ultraviolet light is known to trigger lupus (McGrath, 1999), 
smoking and obesity may increase the risk of RA (Karlson et al., 1999; Shovman, 2000). 
D-penicillamine, a medication has been implicated in the development of autoimmune 
diseases such as lupus and glomerulonephritis (Brik et al., 1995). Viruses have been 
identified as the etiologic agent of several autoimmune diseases (Krieg et al., 1989, 1991; 
Krieg and Steinberg, 1990; Steinberg et al., 1990; Rosa and Bamaba, 1998). The 
mechanism by which viruses and other infections agents initiate autoimmunity are 
complex and may include structural similarity, increased HLA expression, polyclonal B 
cell activation and alteration of self antigens (Shoenfeld and Isenberg, 1989), cross 
reactive peptide presentation, determinant spreading, upregulation of MHC, upregulation 
of cellular and extracellular processing, apoptosis, infection of professional antigen 
presenting cells and subversion of T cell responses (Rosa and Bamaba, 1998). Hepatiiis 
C virus has been found to be responsible for most cases of mixed cryoglobulinemia 
(Agnello et al., 1992) and even some cases of polyarteritis nodosa (Carson et al., 1993), 
Sjogren's syndrome (Ramos-Casals et al., 2000) and lupus like syndrome (Garcia-
Carrasco et al., 1997). Additionally, retroviruses (i.e. human immunodeficiency viruses) 
have been implied in a constellation of autoimmune manifestations, like Sjogren's and 
lupus like syndrome (De Clerk et al., 1988). The autoantibodies associated with HIV 
infection include antinuclear antibodies, rheumatoid factor, anti-cardiolipin antibodies, 
anti platelet, anti-red blood cell and anti-lymphocyte antibodies. 
Autoimmune diseases can be classified into two broad, but overlapping, groups: 
Organ-specific and non-organ-specific (or systemic) autoimmune diseases. Hemolytic 
anaemia, Hashimoto's thyroiditis, mysthenia gravis, type I insulin dependent diabetes and 
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Grave's disease are few examples of organ specific diseases. Autoantibody or cell 
mediated reactions against a specific target antigen, located in a specialized cell, tissue or 
organ occurs. In systemic autoimmune diseases, by contrast, tissue injury and 
inflammation occur in multiple sites in organs. SLE is a classic example of systemic 
autoimmune diseases. 
Systemic Lupus Erythematosus 
Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease 
involving both humoral and cellular aspects of the innate and acquired immune systems. 
Females compose approximately 9 out of every 10 cases, with onset typically occurring 
during the prime child bearing years (Klippel, 1997). The clinical expression of SLE is 
extremely varied, but the most common findings include fever, erythematosus rash, 
arthritis, serositis and nephritis. Skin photosensitivity, oral ulcers, hematologic disorders 
and neurological abnormalities are also seen. SLE is characterized by the production of 
multiple autoantibodies, typically antinuclear and anti-DNA antibodies (Tan, 1989; 
Shefner et al, 1990, Steinberg 1992; Harada et ai, 1994; Petri, 1996). In some patients 
antibodies are also produced against platelets, lymphocytes, cellular antigens such as 
polysaccharides (Kashihara et al, 1993), phospholipids (Tiikainem et al, 1991), cell 
membrane structures (Jacob et al, 1986) and nucleoproteins (DNA-histone, nuclear 
ribonucleoprotiens like Sm and Mo, cytoplasmic ribonucleoproteins like Ro=SSA and 
La=SSB, ribosomes) (StoUar, 1981). Some of these autoantibodies may be directly 
pathogenic e.g. anti-phospholipid antibodies are associated with an anticoagulant 
syndrome (Mills et al, 1994). However, most of the symptoms of the disease result from 
the formation of immune complexes (ICs) that deposit within various tissues, where they 
recruit complement and inflammatory cells to cause disease (Petri, 1996). Many of these 
IC-forming autoantibodies in SLE target nuclear antigens that are released into 
circulation (including DNA, histones, and ribonucleoproteins (Tan, 1989; Shefhar et al, 
1990). 
The anti-DNA autoantibodies in SLE can bind to both denatured single stranded 
(ss) and native double stranded forms of DNA (dsDNA) (Stollar 1981; Voss 1988; Tan, 
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1989), while anti-ssDNA antibodies can be found in other autoimmune diseases, anti-
dsDNA antibodies are diagnostic for SLE (Reeves et al, 1994; Petri, 1996). However 
both forms of anti-DNA antibodies have been implicated in the pathogenesis of IC-
mediated glomerulonephritis in SLE. 
Major organ system involvement may occur in the heart, lungs, kidneys and 
central nervous system. Recent studies have shown that immune liver disease, mainly 
autoimmune cholangiopathy, may be an important, clinical manifestation of SLE 
(Heyman et al, 2002). The incidence of SLE has more than tripled over the past four 
decades and the rate of survival for individuals with this condition has significantly 
improved (Urowitz et al, 1997; Uramoto et al, 1999). Possible explanations for an 
increase in incidence of SLE over time includes an increased exposure to hormones such 
as oral contraceptives (Sanchez-Guerrero et al, 1997) and estrogen in hormone 
replacement therapy (Sanchez-Guerrero et al, 1995), exposure to ultraviolet light 
(Zamansky, 1985; Petzelbauer et al, 1992) and smoking (Brown et al, 1995). 
The cause of SLE is unknown. The presence of multiple autoantibodies and other 
immunologic abnormalities like decreased suppressor T-cell function, spontaneous B cell 
activation (Budman et al, \911\ Becker et al, 1981; Klinman and Steinberg, 1987), 
impaired macrophage function, point to the basic defects in immunoregulatory controls 
that normally maintain immune tolerance to self antigens (Steinberg et al, 1990). 
Contributory factors may be genetic (Fessel, 1988; Amett, 1997), hormonal or 
environmental in nature (Klippel 1997; Kardestrucer and Franklin, 1997). Genetic 
influence is suggested by family clusters of SLE, significant (approx 25%) concordance 
of SLE in monozygotic twins as compared to the dizygotic twins (2-3%) (Reichlin et al, 
1992; Deapen et al, 1992; Block 1993; Jarvinen and Aho, 1994) and familial aggregation 
studies indicate a sibling risk ratio of at least 10 (Vyse and Todd, 1996). The genetic 
hypothesis in SLE is also supported by the high incidence of SLE in patients with certain 
complement deficiencies (Ci, C2 and C4) (Walport, 1993) and association of disease and 
autoantibody production with HLA class II alleles (Amett, 1997). For the better 
understanding of the genetic basis for susceptibility to SLE, a number of groups have 
initiated genome wide marker screens in human SLE (Gaffney et al, 2000; Lindqvist, 
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2000; Shai et al, 1999). A key issue for identification of susceptibility for human SLE is 
to reduce the genetic heterogeneity and possibly also the phenotypic complexity. 
Hormonal influence is suggested by 9:1 female : male ratio of SLE. 
Environmental factors associated with SLE includes several drugs such as 
procainamide, hydralazine, methyldopa and chlorpromazine. Drug induced lupus is a 
syndrome resembling mild SLE which can complicate treatment with certain apparently 
unrelated therapies. Drug induced lupus erythematosus is reversible, when drug therapy 
is stopped, the symptoms gradually fade. In amiodarone (an iodinated derivative of 
benzoflirane) induced lupus, various markers of systemic disease activity such as 
circulating immune complexes, ANAs and specific antibodies of the high class have been 
found (Sheikhzadeh and Schnabel, 2002). In one case, zinc supplementation appears to 
have aggravated drug-induced SLE (Fjellner, 1979). Similarly, envirormiental pollution 
and industrial emissions may also trigger SLE-like symptoms in some people 
(Kardestrucer and Franklin, 1997). Ultraviolet from sun exposure is a commonly 
recognized trigger of lupus (Millard et al, 2000). Some chemicals found in dyes, such as 
hydrazine (Reindenberg et al, 1983) and tartrazine (Pereyo, 1986) are also thought to 
cause SLE. A recent study in non-autoimmune prone mice treated with pristane, a 
hydrocarbon derived fi-om the metabolism of chlorophyll shows the production of 
antichromatin and anti-DNA antibodies and accelerated onset of renal disease (Yoshida 
et al, 2002). The development of lupus following pristane treatment is cytokine 
dependent. Thus environmental variables may influence the levels of cytokines that 
promote autoantibody formation in pristane-induced lupus, such as IC-G, IFNy and lL-12 
(Richards et al, 1998, 2001). 
Autoantibody production in murine and human lupus has been attributed to (i) the 
selective stimulation of autoreactive B cells by self antigens (or antigens cross reactive 
with self) (Hardin, 1986) or (ii) a more generalized process of immune dysregulation 
leading to multiclonal B cell activation (Budman et al, 1977; Beckar et al, 1981; 
Klinman and Steinberg, 1987 a,b). In SLE, the entire pathway of B cell maturation and 
antibody production is excessively activated (Steinberg et al, 1990). SLE associated 
autoantibodies are thought to originate from natural autoantibody secreting B cells. It is 
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hypothesized that certain clones of the expanded primary B cell repertoire are selected to 
differentiate into harmful high autoantibody-secreting clones. Complexes formed by the 
association of DNA and DNA-binding proteins possess a selective advantage over other 
autoantigens to induce the differentiation of certain B cell clones and in SLE-autoimmune 
response (Gilbert et al, 1996). Its been firmly established that antibodies to DNA are the 
result of antigen-selective B cell stimulation and that DNA itself indeed represents the 
major B cell stimulus (Isenberg, 1994). Recent studies have shown that IgGi and IgOa 
subclass antibodies to nucleohistone and to dsDNA are the predominant subclasses found 
in the plasma of lupus patients with renal disease (Bijl et al, 2002). A significant rise in 
anti-dsDNA IgGi is seen in 91% of the patients prior to a renal relapse. 
Anti-dsDNA antibodies are of considerable diagnostic value and are thought to be 
involved in the pathogenesis of SLE. Fluctuations in anti-dsDNA antibody levels are also 
used as markers for disease activity and exacerbations. However studies show that anti-
dsDNA antibodies are present prior to clinical diagnosis of SLE (Arbuckle et al, 2001), 
but their level increase as the disease progresses. Complement receptor proteins CRl and 
CR2 also have role in B cell activation. Expression of CRl and CR2 on B cells is reduced 
in patients with SLE (Prodeus et al, 1998). Abnormalities in CRl and CR2 may be 
linked to the production of autoantibodies by modifying the effect of other SLE genes. 
Recently the role of Cr2 gene, gene coding for these receptor proteins has been indicated 
in SLE (Wue/a/., 2002). 
B-cell activation generally requires T cell help. T cells have been cloned from 
lupus-prone mice and these were found to stimulate the production of anti-DNA 
antibodies and renal lesions when injected. Obligatory and enhanced T cell help for B 
cells is shown in SLE lymphocytes by prolonged expression and co-stimulatory 
interaction of the helper T-cell surface ligand CD40 (CD40L) with B cell receptor CD40 
(Desai et al. 1996; Koshi et al, 1996). The interaction of CD40L on activated T cells 
with CD40 on B cells, induces B cell proliferation and formation of germinal centers. 
Within germinal centers, further cell to cell interactions leads to B cell maturation 
through Ig isotype switching, somatic mutation, clonal expansion of high-afFinity B cells 
and terminal differentiation to plasma cells (Reiser and Stadecker 1996; Lindhout et al. 
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1997; Tarlinton 1998). Blockade of CD40L has been shown to delay the onset of disease 
in SLE-prone mice and to stabilize or reverse existing renal disease (Mohan et al, 1995; 
Kalled et al, 1998). Recent studies in SLE-prone mice (NZB x NZW) Fi show that an 
anti-CD40L monoclonal antibody administered to prenephritic mice inhibits both T cell 
activation and T cell-dependent B cell activation (Huang et al, 2002). 
T cell abnormalities, B cell hyperactivity and abnormal cytokine production have 
been implicated to be of pathogenic importance in SLE. SLE patients have an increased 
production as well as increased serum level of the type 2 cytokines IL-10 and lL-6. 
Serum IL-10 levels correlates with the titre of anti-dsDNA antibodies in SLE patients 
(Grondal et al, 2000). The role of these cytokines in the pathogenesis of SLE is 
unknown, but theoretically, IL-10 could stimulate peripheral blood mononuclear cells of 
SLE patients to produce autoantibodies, and thus be important in the excessive 
autoantibody production that is characteristic of SLE (Llorente et al, 1995). High IL-10 
production is reported in healthy relatives of SLE patients in multi case families, 
indicating that this tendency may be a genetic factor in pathogenesis (Llorente et al, 
1997). 
Autoreactive T and B lymphocytes during development (Cohen et al, 1992) and 
after completion of an immune response are removed by apoptosis (Thompson, 1995). 
Abnormal T cell activation and cell death underline the pathology of systemic lupus 
erythematosus (Elkon, 1994; Perl and Banki, 1999). Lupus T cells exhibit both enhanced 
spontaneous apoptosis and defective activation-induced cell death. T cell activation via 
CD3/CD28 co-stimulation induces mitochondrial hyperpolarization. With hyper-
polarization and extrusion of H"^  ions from the mitochondrial matrix, the cytochromes 
within the electron transport chain become more reduced, which favours generation of 
ROS (Stryer, 1988). Mitochondrial hyperpolarization and increased ROS production play 
crucial roles in altered IL-10 responsiveness in SLE ultimately leading to increased 
spontaneous cell death in patients with SLE (Gergely, 2002). 
Based on intensive research during the last decades, three main mechanisms 
might contribute to the development of SLE (Lorenz et al, 2001). 
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1. Increased amounts and abnormal presentation of potential autoantigens including 
nuclear antigens. 
2. T cell dependent stimulation of B cells for the production of antinuclear 
antibodies. 
3. Anti-dsDNA as well as immune complex mediated organ damages. 
In SLE, the pathogenic concept mainly focuses on a dysregulation of programmed 
cell death, giving the immune system the chance to form autoantibodies against nuclear 
constituents like dsDNA or ribonucleoproteins (RNP) (Lorenz et ai, 2001). Apoptosis 
dysregulation plays a key role in autoimmune diseases (Mountz and Zhou, 2001; Emlen 
et ai, 1994). Apoptosis is most important for the immune system in regulating ceil 
growth. Control of apoptosis is critical for the homeostasis of many organ like the 
immune system (Lorenz et ai, 2001). During apoptotic breakdown many nuclear 
constituents are post translationally modified, possibly altering antigenicity. Failure to 
appropriately achieve programmed cell death and to clear apoptotic cell fragments is 
discussed as a key pathogenic factor leading to autoimmunity. This could be due to 
failures to kill an autoreactive cell or by inducing (auto) immunity against modified 
cellular constituents. Potential autoantigens might be sequestered during apoptosis and 
become accessible for immuno-competent cells. There might be two major mechanism 
which could lead to an increased amount of circulating nuclear antigens in SLE patients: 
an increased amount of apoptosis or a decreased clearance of apoptotic cell material as an 
important etiopathogenic event in SLE. These findings might explain the increased levels 
of DNA and nucleosomes as reported in the circulation of SLE patients (Lorenz et al., 
\998;Pemioketal., 1998). 
RoleofROSinSLE 
Oxygen derived free radicals are important in both natural and acquired 
immunity. Neutrophil and macrophage phagocytosis stimulates various cellular processes 
including the "respiratory burst" whereby increased cellular oxygen uptake results in the 
production of the potent oxidant bactericidal agents (Joseph, 2000) thereby killing 
bacteria and regulating the process of acute inflammation (Halliwell, 1982). 
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Inflammatory response is thus advantageous for the organism. However, abnormal over 
activation of phagocytes with consequent exacerbation of reactive oxygen metaboHtes 
production may damage surrounding tissues and lead to diseases such as SLE (Proctor 
and Reynolds, 1984; Southern and Powis, 1988; Halliwell and Gutteridge, 1989). 
ROS are implicated in the inflammatory, autoimmune, connective tissue disease, 
systemic lupus erythematosus, particularly in respect of processes leading to the 
formation of pathogenic anti-DNA antibodies. Accumulating evidence suggests that ROS 
mediate apoptotic cell death as intracellular ROS levels increase and cells undergo 
apoptosis (Gardner e/a/.. 1997; Lelli e/a/., 1998; Lieberthal era/., 1998). 
Recent studies show that mitochondrial hyperpolarization, increased ROS 
production and cytoplasmic alkalinization plays crucial roles in altered IL-10 
responsiveness in SLE (Gergely, 2002). 
There is growing evidence for a role of oxidative stress in the aetiology and 
pathogenesis of SLE (Evans, 2000). DNA is a major target for oxidants resulting in 
increased autoantigen production, enhancement of antigenicity and altered cell functions 
(Blount et ai, 1990; Ara and Ali, 1992; Cooke et al, 1997). ROS-DNA has been found 
to have increased binding with naturally occurring anti-DNA autoantibodies in SLE as 
compared to its unmodified form (Ara and Ali, 1992; Arjumand et al, 1997; Alam and 
Ali, 1999). Defective DNA damage processing has been reported in SLE. Lymphocytes 
isolated from patients suffering from SLE contain increased levels of 8-oxodG in DNA 
(Bashir et ai, 1993), a marker of oxidative damage. An increase in serum 8-oxodG were 
detected in SLE patients implying a defect in the processing of 8-oxodG in SLE (Evans at 
al. 2000). 
Malignancies are more common in most autoimmune diseases as compared to the 
general population (Ramos Casals et al, 2000). 
Cancer 
Cancer may be regarded as a group of disease characterized by an (i) abnormal 
growth of cells (ii) ability to invade adjacent tissues and even distant organs and 
(Weinberg, 1996). (iii) The eventual death of the affected patient if the tumor has 
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progressed beyond that stage when it can be successfully cured or removed. The 
carcinogenic process, therefore, appears to be one cellular evolution (Farber, 1973) 
The major categories of cancer are (a) Carcinomas, which arise from epithelial 
cells lining the internal surfaces of the various organs and from the skin epithelium, (b) 
Sarcomas, which arise from mesodermal cells constituting the various cormective tissue, 
and (c) Lymphomas, myelomas and leukemias arising from the cells of bone marrow and 
immune system. Molecular changes in carcinogenesis proceeds through at least 3 distinct 
stages. 
1. Initiation of cancer may involve changes in DNA. This could be in terms of an 
altered base, a miscoding lesion, rearrangements of segments of DNA, the 
activation and modulation of gene expression by neighbouring base sequences, 
gene duplication and activation of oncogenes (Cavenee and White, 1995). By 
selectively modifying gene expression in initiated cells, tumor promoters can 
illicit the production of clonally derived benign growth. These tumors can be 
converted into rapidly growing malignant neoplasms through further DNA 
damage (Guyton and Kensler, 1993). The initiated cells expand into nodules, 
papillomas or polyps, which can act as population for the ultimate development of 
cancer. Thus cancer progression is a multi step process. 
2. Promotion: In this stage the initiated cell is exposed to a tumor promoter which 
causes these cells to undergo phenotypical clonal expansion. Promotion may be 
enhanced by the creation of a stimulus, and a selective or differential inhibition of 
surrounding cells (Farber, 1984). 
3. Malignant conversion: Cellular growth is further deregulated thus proceeds 
uncontrolled. As tvunor progresses, sensitivity to dietary compounds, inhibitors of 
growth and enhancers of differentiation gradually disappear until the tumor 
becomes progressively more autonomous and controlled only by more drastic 
interventions (Guyton and Kensler, 1993). 
Cancer like all other chronic diseases has multifactorial aetiology, which includes 
both genetic and environmental factors (Gouriey et ai, 1992). There is probably a 
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complex inter-relationship between hereditary susceptibility and environmental 
carcinogenic stimuli in the causation of a number of cancers. 
Environmental factors such as sunlight, radiations, pesticides and medications are 
known to augment cancer (Anathaswamy and Pierceall, 1990; Liehr, 1997). Dietary 
factors such as high fat diet, beef consumption, food additives and contaminants have 
been related to cancer (Ames, 1983). Consumption of tobacco is a major cause for cancer 
of mouth, lung, larynx, pharynx and pancreas (WHO, 1983). Alcohol consumption 
(Eskelson et al, 1993) and exposure to benzene, arsenic, cadmium and chromium have 
also been known to cause cancer (Kasai and Nishimura, 1984; Frenkel, 1992; Kolachana 
etal, 1993;Lagorioe/a/., 1994). 
The relentless attack of reactive oxygen species on DNA appears to be a 
significant factor in the development of cancer (Frenkel, 1992; Leanderson, 1993; Feig el 
al., 1994; Erhardt et al., 1997). ROS induced mutagenic lesions are thought to initiate and 
promote cancer (Ames, 1989; Sadani and Nadkarin, 1996; Pryor, 1997). 
Role o f R O S in Cancer 
DNA oxidation is a major contributor to human cancer through three major 
sources: smoking, chronic inflammation and endogenous oxidants such as leakage from 
mitochondria (Ames et a!., 1993; Ames et al., 1995; Loft and Poulsen, 1996; Jacob and 
Burri, 1996; Hagen et al., 1997). ROS can cause DNA base changes, strand breaks, 
damage to tumor-suppressor genes and enhanced expression of protooncogenes (Cerutti, 
1994; Jackson, 1994). Oxidative stress has been shown to induce malignant 
transformation of cells in culture (Weitzman and Gordon, 1990; Zimmerman and Cerutti, 
1984). However the development of himian cancer depends on many other factors, 
including the extent of DNA damage, antioxidant defences, DNA repair systems, the 
efficiency of removal of oxidized nucleosides before they are incorporated into DNA, 
and the cytotoxic effects of ROS in large amounts, as well as their growth promoting 
effects in small amounts (Burdon et al., 1995). 
Persistent excessive oxidative DNA damage may transmit signals to the cellular 
components, including the tumor suppressor protein p53 and may trigger apoptosis 
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(Sarafian, 1994; Slater et ai, 1995; Buttke and Sandstrom, 1995). The anti apoptotic gene 
bcl-2 is also an oncogene. It may protect cells by inhibiting ROS-induced lipid 
peroxidation (Hockenbery et al, 1993; Sarafian and Bredesen 1994) thus preventing the 
apoptotic death of 'initiated' cells. Down regulation of the bcl-2 gene by the p53 tumor 
suppressor protein in human breast cancer cells has been reported (Haider et al, 1994). 
'OH radical induced DNA damage can activate the K-ras 43 and c-Raf-1 oncogene by 
causing point mutation and deletion leading to carcinogenesis (Jackson, 1994). 
Extracellular ROS generation seems to represent a hallmark of transformed fibroblasts 
(Irani et al, 1997; Bauer, 2000). Extracellular ROS of transformed cells are key elements 
for intercellular induction of apoptosis (Herdener et al, 2000; Paul and Bauer, 2001; 
Heigold and Bauer, 2002; Schimmel and Bauer, 2002). 
Studies have been attempted to identify mutations that are caused by ROS damage 
to DNA, with the aim of ascertaining their association with cancer (Cerutti, 1994). 
Although all the four bases are modified by ROS, the mutations are usually related to 
modifications of GC base pairs, while modifications of AT base pairs rarely lead to 
mutation (Retel et al, 1993). The 'OH from ionizing radiations generally induces GC to 
CG or AT base pair substitutions (Retel et al, 1993), while singlet oxygen induced DNA 
damage is targeted selectively at guanine residues (Costa de Oliveira et al, 1992). In 
human tumors, G to T transversion are among the most frequent hot spot mutations in the 
p53 suppressor gene (Harris and Hollstein, 1993). ROS may also induce conformational 
changes in the DNA template, thereby diminishing the accuracy of replication by DNA 
polymerases (Reid and Loeb, 1993). 
ROS may also cause damage to proteins and lipids, leading to lipid peroxidation 
(Ames, 1989). Excess ROS generation may damage DNA polymerases thereby altering 
their fidelity (Stadtman, 1993) and also affect the activity of DNA repair enzymes. Low 
levels of unsaturated fatty acids renders the membrane of tumor cells rigid (Bartoli et al. 
1990). The shape of cell is determined by the spatial arrangement of DNA superdomains 
bounded by lipid bridges which are selectively cleaved by ROS (Olovnikov, 1996) thus 
giving tumors their irregular shape. 
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Cases of limg cancer are mostly related to smoking. Cigarette smoke is rich in 
carcinogens such as nitrosoamines, acrolein, and carcinogenic hydrocarbons. ROS may 
also contribute to cancer development since smoke is rich in ROS (Pryor and Stone, 
1993; Eiserich et al, 1994). Higher levels of oxidative DNA base damage has been 
reported in lung cancer tissue (Olinski et al., 1992). 
Liver cancer is often associated with chronic infection with hepatitis B or C 
(Blumberg et al., 1975). Chronic hepatitis (Stein, 1991) is associated with the presence of 
inflammatory cells, presumably generating ROS. Increased levels of 8-OHdG have been 
detected in DNA from livers with chronic hepatitis (Hagen et al., 1994; Shimoda el al.. 
1994). 
Oxidative damage may be involved in the development of breast cancer. 
Increased steady state levels of DNA base damage, with a pattern characteristic of *011 
attack, have been reported in DNA from invasive ductal carcinoma (Malins and 
Haimanot, 1991; Malins et al, 1993). A 9-fold increase in 8-OHdG, 8-hydroxyadenine 
and 2,6-diamino-4-hydroxy-5-formamidopyrimidine has been found in this case. DNA 
damage by ROS is also implicated in inflammatory breast disease (Jaiyesimi, et al.. 
1992). 
The age-related increase in the proportion of *0H -induced mutagenic base lesions 
is likely a significant factor in prostrate cancer development (Malins et al, 2001). The 8-
0X0 lesions, formed from various reactive oxygen species may alter the conformational 
properties of strands at the replication fork (Sen Gupta et al, 1992; Feig et al, 1994; 
McAuley-Hecht et al, 1994; Berwick and Vineis, 2000) thus affecting the selectivity of 
polymerases, the proof reading capability of repair enzymes and the fidelity of the 
transcriptional machinery (Malins et al, 2000). 
Oxygen is needed for survival, but constant attack on DNA by ROS may lead to 
cancer development. Understanding the mechanisms by which these chemical changes 
relate to alteration in gene expression may lead to new concepts and novel ways of 
preventing cancer. 
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Objective of the Present Study 
Free radicals are produced in living cells by normal metabolism and by exogenous 
sources such as carcinogenic compounds and ionizing radiations. Of these radicals, the 
highly reactive hydroxyl radical ('OH) causes damage to DNA, also termed as oxidative 
damage. Oxidative damage to DNA are the basis of several pathogenic functions in SLE, 
like influencing the production or reactivity of autoantibodies, enhancing antigenicity and 
inducing cellular dysfunction. Oxidative damage to DNA is also implicated in 
mutagenesis, carcinogenesis and aging. 
In the present work, plasmid Bluescript DNA from E.coli DHsa cells was purified 
on cesium chloride gradient and modified with *0H generated by UV irradiation in the 
presence of hydrogen peroxide. Native calf thymus DNA fragments of approximately 400 
bp were also isolated and subjected to 'OH modification. The modifications on DNA 
were studied by UV spectroscopy, fluorescence spectroscopy, thermal denaturation 
studies, nuclease SI digestibility and restriction enzyme digestion. Polyclonal antibodies 
against ROS-plasmid DNA were generated in experimental animals. The repertoire of 
specificities of induced antibodies was evaluated by their binding to various nucleic acid 
polymers. In order to assess the possible role of ROS-modified epitopes in the aetiology 
of autoimmune diseases, sera from various SLE patients were studied for their 
recognition of native and ROS-modified plasmid DNA. ROS-modified DNA was also 
used as a probe to detect oxidative damage to DNA in various types of cancers. 
cc/^^e4€^n€yn^:l/ 
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MATERIALS 
Calf thymus DNA, nuclease SI, bovine serum albumin, anti-human/anti-rabbit 
IgG-alkaline phosphatase conjugate, p-nitrophenyl phosphate, ethidium bromide, 
Coomassie Brilliant Blue G-250 and R-250, sodium dodecyl sulphate, Tween-20, 
Freund's complete and incomplete adjuvants, cesium chloride, ampicilin and agarose 
were purchased from Sigma Chemical Company, U.S.A. Micrococcal nuclease, synthetic 
polynucleotides, Ficoll 400, xylene cyanole FF were purchased from Pharmacia Fine 
Chemicals, Sweden. Tryptone, yeast extract, bacto-agar were procured from Difco, 
U.S.A. Folin-Ciocalteau reagent and Blue Dextran 2000 were purchased from Centre for 
Biochemical Technology, New Delhi. Protein-A agarose, 100 bp ladder and Eco RI was 
from Genei, India. Absolute ethanol was obtained from BDH Laboratory Supplies. 
England. 
Polystyrene microtitre flat bottom ELISA plates having 96 wells (7 mm diameter) 
were purchased from NUNC, Dermiark. Acrylamide, ammonium persulphate, 
biascrylamide, N,N,N,N-tetramethylethylene diamine (TEMED) were from Bio-Rad 
Laboratory U.S.A. EDTA (disodium salt), chloroform, isoamyl alcohol, methanol, 
glacial acetic acid were from Qualigens, India. Diphenylamine was chemically pure. All 
other reagents/chemicals were of the highest analytical grade available. 
Equipments 
Shimadzu UV-240 Spectrophotometer equipped with thermo-programmer and 
controller unit, ELISA microplate reader, Elico pH meter model LI-120, ultraviolet lamp 
(Vilber Lourmat, France), agarose gel electrophoresis assembly (GNA-100) and gradient 
mixer GM-1 (Pharmacia, Sweden), Beckman ultracentriftjge, Avanti 30 table top high 
speed refrigerated centrifuge (Beckman, U.S.A.), polyacrylamide gel elecfrophoresis 
assembly (Bio-Rad, U.S.A.) and fluorimeter (Hitachi, Japan) are major equipments used 
in this study. 
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Collection of Sera and Blood Samples 
Normal human sera were obtained from healthy subjects. SLE sera were obtained 
from outdoor and indoor patients of the Department of Medicine, All India Institute of 
Medical Sciences, New Delhi. The SLE sera showed high titre anti-DNA antibodies and 
fiilfilled the American College of Rheumatology revised criteria for the classification of 
SLE (Amett et al., 1988). Sera of cancer patients proven with histopathological diagnosis 
were obtained from J.N. Medical College Hospital A.M.U., Aligarh. Sera were 
decomplemented by heating at 56°C for 30 min and stored in aliquots at -20°C. 
METHODS 
Determination of DNA Concentration 
DNA concentration was estimated colorimetrically by the method of Burton 
(1956) using diphenylamine reagent. 
(a) Crystallization of diphenylamine 
Diphenylamine (2g) was dissolved in 200 ml boiling hexane. After adding 0.5g of 
activated charcoal, the hot mixture was filtered through Whatman No. 1 filter paper and 
the filtrate was kept overnight at 4°C. The crystals of diphenylamine were dried at room 
temperature and stored. 
(b) Preparation of diphenylamine reagent 
750 mg of recrystallized diphenylamine was mixed with 50 ml of glacial acetic 
acid and 0.75 ml concentrated sulphuric acid. The reagent was prepared fresh before use. 
(c) Procedure 
One ml of DNA sample was mixed with 1.0 ml of IN perchloric acid and 
incubated at 70°C for 15 min. 100 ^l of 5.43 mM acetaldehyde was added followed by 
2.0 ml of freshly prepared diphenylamine reagent. The contents were mixed and 
incubated at room temperature for 16-20 hr. Absorbance was read at 600 nm and the 
35 
concentration of DNA in unknown samples was determined from a standard plot of calf 
thymus DNA purified free of RNA and proteins. 
Determination of Protein Concentration 
Protein was estimated by the methods of Lowry et al. (1951) and Bradford 
(1976). 
Protein estimation by Folin's-phenol reagent 
The protein estimation by this method utilizes alkali (to keep the pH high), Cu ^ 
ions (to chelate proteins) and tartarate (to keep the Cu^ "^  ions in solution at high pH). 
(a) Folin-Ciocalteau reagent 
The reagent was purchased from Centre for Biochemical Technology, New Delhi 
and diluted 1:4 with distilled water before use. 
(b) Alkaline copper reagent 
The components of alkaline copper reagent were prepared as follows: 
(i) 2 percent sodium carbonate in 100 mM sodium hydroxide. 
(ii) 0.5 percent copper sulphate in 1 percent sodium potassium tartarate. 
The working reagent was prepared fresh before use by mixing components (i) and 
(ii) in the ratio of 50:1. 
(c) Procedure 
To 1 ml of protein sample was added 5 ml of alkaline copper reagent and 
incubated for 10 min at room temperature. 1 ml of working Folin-Ciocalteau reagent was 
added and the tubes were read at 660 nm after 30 min. The concentration of protein in 
unknown sample was determined from a standard plot of bovine serum albimiin. 
Protein estimation by dye-binding metliod 
This assay is based on color change when Coomassie Brilliant Blue G 250 in 
acidic medium, binds strongly to protein hydrophobically and at positively charged 
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groups (Bradford, 1976). In the environment of these positively charged groups, 
protonation is suppressed and a blue color is observed (X,nax=^ 595 nm). 
(a) Dye preparation 
100 mg Coomassie Brilliant Blue G-250 was dissolved in 50 ml of 95% ethanol 
and 100 ml of 85% (v/v) orthophosphoric acid was added. The resuhing solution was 
diluted to a final volume of 1 litre and filtered through Whatman No. 1 filter paper to 
remove undissolved particles. 
(b) Protein assay 
To 1 ml of solutions containing 10-100 ^g protein was added 5 ml of dye solution 
and contents mixed by vortexing. The absorbance was read at 595 mn after 5 min against 
a reagent blank. 
Purification of Calf Thymus DNA 
Commercially obtained calf thymus DNA was purified free of proteins and single 
stranded regions as described by Ali et al. (1985). DNA (2 mg/ml) was dissolved in 
0.1 X SSC buffer (15 mM sodium citrate and 150 mM sodium chloride, pH 7.3) and then 
mixed with an equal volume of chloroform-isoamyl alcohol (24:1) in a stoppered 
container and shaken for 1 hr. The aqueous layer containing DNA was separated from the 
organic layer and re-extracted with chloroform-isoamyl alcohol. The DNA was 
precipitated with two volimies of cold absolute ethanol and collected on a glass rod. After 
drying in air, the DNA was dissolved in acetate buffer (30 mM sodium acetate containing 
30 mM zinc chloride, pH 5.0) and treated with nuclease SI (150 units/mg DNA) at 37°C 
for 30 min to remove single stranded regions. The reaction was stopped by adding one-
tenth volume of 200 mM EDTA, pH 8.0. The nuclease SI treated DNA was extracted 
twice with chloroform isoamyl alcohol and finally precipitated vdth two volumes of cold 
ethanol. The precipitate was dissolved in phosphate-buffered saline (PBS) (10 mM 
sodium phosphate containing 150 mM sodium chloride), pH 7.4. 
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Fragmentation of Calf Thymus DNA 
Micrococcal nuclease was used to digest purified DNA to obtain smaller 
fragments (AH et al, 1985). Purified DNA (2 mg/ml) in 6 mM Tris, 100 mM NaCl and 2 
mM CaCl2, pH 8.0 was treated with 0.25 units of micrococcal nuclease per mg DNA at 
37°C for 6 min. The reaction was stopped by adding one-tenth volume of 200 mM 
EDTA, pH 8.0. The mixture was extracted twice with chloroform-isoamyl alcohol and 
fragmented DNA was precipitated with cold absolute ethanol and dissolved in 30 mM 
acetate buffer, pH 5.0 containing 30 mM ZnC^. The DNA was digested with nuclease SI 
(150 units/mg DNA) at 37°C for 30 min. The reaction was stopped with one-tenth 
volume of 200 mM EDTA, pH 8.0. The digested DNA fragments were extracted twice 
with chloroform-isoamyl alcohol and precipitated with cold absolute ethanol. The DNA 
fragments were then dissolved in Tris buffered saline (TBS) pH 8.0 and separated on the 
basis of size by gel filtration on Sepharose 4B column (46.0 cm x 1.2 cm) equilibrated 
with TBS. Fractions of 4 ml were collected. The size of the DNA fragments was 
determined by polyacrylamide gel electrophoresis (PAGE). 
Polyacrylamide Gel Electrophoresis 
Nucleic acid samples were subjected to PAGE under non-denaturing conditions as 
described by Laemmli (1970). The following stock solutions were prepared: 
(a) Acrylamide-bisacrylamide (30:0.8) 
Thirty gm acrylamide and 0.8 gm bisacrylamide was dissolved in distilled water 
to a final volume of 100 ml. The solution was filtered and stored at 4°C in an amber 
coloured bottle. 
(b) Resolving gel buffer 
Thirty six gm Tris was dissolved in 48 ml of 1 N HCl, pH adjusted to 8.8 and 
final volume made upto 100 ml with distilled water. 
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(c) Stacking gel buffer 
Six gm Tris was dissolved in 40 ml distilled water, pH adjusted to 6.8 with IN 
HCl and final volume made upto 100 ml with distilled water. 
(d) Electrode buffer 
The electrophoretic buffer used was TAE (40 mM Tris, 1.14 ml glacial acetic acid 
and 1 mM EDTA), pH 7.9. 
(e) Procedure 
The PAGE assembly was set up and the glass plates separated by 1.5 mm thick 
spacer were sealed with 1% agarose from the sides and bottom. The non-denaturing gel 
was prepared and poured between the glass plates and allowed to polymerize at room 
temperature. Nucleic acid samples were mixed with one-tenth volume of'stop mix' (30% 
Ficoll, 0.025% xylene cyanole FF and 500 mM EDTA in 10 times concentrated TAE 
buffer) and applied onto the gel. The gel was electrophoresed for 8-10 hr at room 
temperature at 80 volts, stained with ethidium bromide (0.5 |ig/ml) and visualised under 
UV light. 
Recipe for 7.5% non-denaturing PAGE 
Acrylamide-bisacrylamide 10.0 ml 
Resolving gel buffer 5.0 ml 
1.5% ammonium persulphate 1.5 ml 
Distilled water 23.5 ml 
TEMED 20.0 i^L 
PAGE for proteins 
A 7.5% resolving gel was layered with 2.5% stacking gel according to the 
composition given in the table. 
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Solutions 
Acrylamide-bisacrylamide 
Stacking gel buffer 
Resolving gel buffer 
Distilled water 
10%SDS 
1.5% ammonium persulphate 
TEMED 
Stacking gel 
2.5 ml 
5.0 ml 
-
11.3 ml 
0.2 ml 
1.0 ml 
15^1 
Resolving gel 
7.5 ml 
-
3.75 ml 
16.95 ml 
0.3 ml 
1.5 ml 
15^1 
Protein samples were mixed with one-fourth volume of sample buffer (10% 
glycerol and 0.002% bromophenol blue in 10 times concentrated 0.5 M Tris-HCl, pH 6.8) 
and applied onto the gel and eletrophoresed at 70 volts for 6-8 hr using Tris-glycine 
buffer (25 mM Tris, 192 mM glycine containing 1% SDS), pH 8.3. The gels were stained 
overnight with 0.1% Coomassie Brilliant Blue R 250 (in 25% isopropanol and 10% 
glacial acetic acid). Destaining was carried out with a mixture of 30% methanol and 10% 
glacial acetic acid. 
Preparation of Plasmid Bluescript DHsa "KS" 
The method for preparing plasmid DNA in a highly purified form involves gentle 
lysis of bacterial cells, centrifugation to remove the bulk of chromosomal DNA and then 
banding of residual DNA in a cesium chloride gradient in the presence of ethidium 
bromide. 
(a) Alkaline extraction method 
This method yields plasmid DNA in a form sufficiently pure to be digestible by 
restriction enzymes or to be used to transform other cells. 
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(b) Material used 
Cell strains and media: Escherichia coli strain DHja was used throughout the 
study. L-broth was used and ampicillin was added at a concentration of 100 mg/ml. 
Reagents I: 50 mM glucose, 10 mM EDTA, 25 mM Tris HCl pH 8.0 II: Alkaline SDS 
solution - 02. N NaOH, 1% sodium dodecyl sulphate III: High salt solution - 5 M 
potassium acetate prepared by dissolving 5 moles of potassium acetate in a minimal 
volume of water, adjusting to pH 4.8 with glacial acetic acid and then adjusting the 
volume to 1 litre. 
Maxi preparation of plasmid DNA 
Plasmid containing E.coli cells were grown in 250 ml L-broth containing 100 
mg/ml ampicillin. After 16 hr incubation at ST^C, with vigorous shaking the culture was 
transferred to two litre L-broth containing 100 mg/ml ampicillin and ftulher incubated for 
16 hr at 37°C (300 rmp). Cells were harvested by centrifugation at 4000 rpm for 10 min 
at 4°C. The supernatant was discarded off. The open centrifuge bottle was left in an 
inverted position to allow all of the supernatant to drain away. The bacterial cell pellet 
was resuspended in 400 ml of ice cold STE (0.1 M NaCl, 10 mM Tris HCl, 1 mM EDTA. 
pH 8.0). The cells were again centriftiged at 6000 rpm for 20 min at 4°C. The supernatant 
was careftiUy removed and cell pellet was suspended in 40 ml of reagent I. After a 30 
min period of incubation at 0°C, 80 ml of reagent II was added and the bottle was shaken 
gently up and down. The bottle was maintained for 10 min at 0°C and then 60 ml of 
reagent III was added. The contents of the bottle were gently mixed by inversion for a 
few seconds resulting in DNA precipitation. The bottle was maintained at 0°C for 15-20 
min to allow most of the protein, high molecular weight RNA and chromosomal DNA to 
precipitate. Centrifugation for 15 min at 4°C yields an almost clear supernatant. The 
supernatant was filtered through cheesecloth. The plasmid DNA was precipitated with an 
equal volume of isopropyl alcohol at room temperature. The precipitate was collected by 
centrifugation at 16,000 rpm for 10 min. The pellet was air dried and dissolved in 
minimal volume of TE (10 mM Tris Hcl, 1 mM EDTA, pH 8.0) and subjected to CsCl 
purification. 
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Purification of Plasmid DNA 
For every milliliter of DNA, 1 gm of solid CsCl was added. The solution was kept 
at 37°C to facilitate the dissolution of the salt. 150 [d of ethidium bromide solution (10 
mg/ml in distilled water) was added for every 10 ml of the DNA/CsCl solution. The EtBr 
solution was mixed immediately with DNA/CsCl solution. The clear red solution was 
transferred to VTa-SO tubes, balanced upto two decimals, sealed and loaded onto rotor. 
The clamps were tightened and the solution centrifuged at 48,000 for 16 at 30°C. The 
plasmid bands were detected by a UV band lamp. The lowermost band was dawn out into 
a syringe. Ethidium bromide was removed by extractions with six-eight washes of water 
saturated n-butanol. The extractions were repeated until the lowermost layer became 
colorless. 
Cesium chloride was removed from DNA by adding five volumes of water and 
precipitating the DNA with twice the volume of cold absolute alcohol at -70°C for 6-8 
hours. The precipitate was recovered by hard spin at 16,000 rpm for 30 min at 4°C. The 
precipitate was washed with 70% alcohol, air-dried and dissolved in minimum volume of 
TE buffer, pH 8.0. 
Reactive Oxygen Species Modification of DNA 
Aqueous solutions of 400 bp calf thymus DNA and plasmid bluescript (0.15 mM 
bp) in PBS, pH 7.4 were irradiated under 254 nm light for 30 min and 15 min 
respectively at room temperature in the presence of hydrogen peroxide (15.1 mM). 
Excess of hydrogen peroxide was removed by extensive dialysis against PBS, pH 7.4. 
Spectroscopic Analysis 
The ultraviolet spectra of native and ROS-plasmid DNA were recorded in the 
wavelength range of 200-400 nm on a Shimadzu UV-240 spectrophotometer. 
Fluorescence emission spectroscopy of native and ROS-plasmid DNA samples 
using ethidium bromide was performed on fluorimeter. 
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Absorption -Temperature Scan 
Thermal denaturation analysis of nucleic acids was performed in order to 
ascertain the degree of modification incurred on the nucleic acids by determining mid 
point melting temperature (Tm). Native and modified samples were subjected to heat 
denaturation on a Shimadzu UV-240 spectrophotometer coupled with a temperature 
programmer and controller assembly (Hasan and AH, 1990). All the samples were melted 
from 30°C to 95°C at a rate of 1.5°C / min after 10 min equilibration at 30°C. The change 
in absorbance at 260 nm was recorded with increasing temperature. Percent denaturation 
was calculated as follows: 
A - A 
Percent denaturation = — ^ x 100 
A - A 
Where, Aj = Absorbance at a temperature T°C. 
Amax = Final maximum absorbance on the completion of 
denaturation (95°C). 
A30 - Initial absorbance at 30°C. 
Hydroxy apatite Column Chromatography 
Hydroxyapatite column chromatography was employed to differentiate nucleic 
acids endowed with different secondary structures. 400 bp DNA and ROS-400 bp DNA 
(in 10 mM Na-phosphate buffer, pH 6.8) were chromatographed on hydroxyapatite 
column as described by Dardalhon and Averback (1998). Batch elution was carried out 
with 125 mM and 250 mM Na-K-phosphate buffer, pH 6.8 at a flow rate of 15 ml/hr and 
fractions of 3 ml were collected and absorbance monitored at 260 nm. 
Nuclease SI Digestibility 
Native and ROS-modified DNA were characterized by nuclease SI digestibility 
(Matsuo and Ross, 1987). One microgram each of native and modified DNA in acetate 
buffer (30 mM each of sodium acetate and zinc chloride, pH 5.0) were treated with 
nuclease SI (20 units/^g DNA) for 30 min at 37°C. The reaction was stopped by adding 
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one tenth volume of 200 mM EDTA, pH 8.0. The digested and control samples were 
subjected to agarose gel electrophoresis. 
(i) Gel preparation 
Agarose (1%) in TAE buffer (40 mM Tris-acetate, pH 8.0 containing 2 mM 
EDTA) was dissolved by heating. The solution was cooled to about 50°C and then 
poured into gel tray and allowed to solidify at room temperature. 
(ii) Sample preparation and loading 
Native and modified DNA samples treated with nuclease SI were mixed with 
one-tenth volume of sample buffer (0.125% bromophenol blue, 30% Ficoll 400, 500 mM 
EDTA in lOX electrophoresis buffer). The samples were loaded in the wells and 
electrophoresed for 2 hr at 30 mA. The gels were stained with ethidium bromide (0.5 
|ag/ml), viewed by illumination under UV light and photographed. 
EcoRI Digestion of plasmid DNA 
(a) EcoRI digestion buffer 
10 mM Tris-HCl, 100 mM NaCl, 10 mM MgCl2, 10 mM 2-mercaptoethanol, 
pH 8.0. 
(b) Storage buffer 
10 mM Tris-HCl, 200 mM NaCl, 0.1 mM EDTA, 7 mM 2-mercaptoethanol, 50% 
glycerol, 200 ^g/ml BSA and 0.2% Triton X-100, pH 7.4. 
(c) Procedure 
One microgram of both native and ROS plasmid DNA was digested with 5 units 
of Eco RI at 37°C for 3 hr. The reaction was stopped by adding one-tenth volume of stop 
mix dye and the samples were loaded in the wells of the submerged agarose gel and 
electrophoresed for 2 hr at 30 mA. 
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Immunization Schedule 
Native and ROS-plasmid DNA (50 ^g) were complexed with an equal volume 
(w/w) of methylated BSA and emulsified with an equal volume of complete Freund's 
adjuvant and injected intramuscularly in female rabbits. Subsequent injections were given 
in incomplete Freund's adjuvant. Each animal received a total of 300 ^g of antigen in the 
course of 6 injections. Blood was collected from marginal vein of the ear, serum was 
separated and decomplemented by heating at 56°C for 30 minutes. Pre-immune serum 
was collected prior to immunization. The sera were stored in small aliquots at -20°C with 
0.1 % sodium azide as preservative. 
Isolation of IgG by Protein-A Agarose 
Serum IgG was isolated by affinity chromatography on Protein-A agarose 
column. Serum (0.3 ml) diluted with equal volume of PBS, pH 7.4 was applied to column 
equilibrated with the same buffer. The wash through was recycled 2-3 times. Unbound 
IgG was removed by extensive washing with PBS, pH 7.4. The bound IgG was eluted 
with 0.58% acetic acid in 0.85% sodium chloride (Goding, 1978) and neutralized with 
1 ml of IM Tris-HCl, pH 8.5. Three ml fractions were collected and read at 251 and 278 
imi. The IgG concentration was determined considering 1.40 OD2go = I.O mg IgG/ml. 
The isolated IgG was then dialyzed against PBS, pH 7.4 and stored at -20°C with 0.1% 
sodium azide. 
Immunological Detection of Antibodies 
Sera were tested for antibodies by immunodiffusion, enzyme linked 
immunosorbent assay and gel retardation assay. 
(a) Immunodiffusion 
Immimodiffusion (ID) was carried out by Ouchterlony double diffusion system. 
Six ml of 0.4%) molten agarose in PBS containing 0.1% sodium azide was poured on to a 
glass petridish and allowed to solidify at room temperature. Wells of 5 mm diameter were 
cut into hardened gel and an appropriate concentration of antigen and antibody was 
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placed in the wells. The petridish was allowed to stand in a moist chamber at room 
temperature for 48-72 hr. The gels were washed with 5% sodium citrate to remove non-
specific precipitin lines. The result was analyzed visually. 
(b) Band shift assay 
For the visual detection of antigen antibody binding and immune complex 
formation, gel retardation assay was performed (Sanford et ai, 1988). A constant amount 
of antigen (native and modified DNA) was incubated with varying amounts of IgG in 
PBS, pH 7.4 for 2 hr at 37°C and overnight at 4°C. One-tenth volume of 'stop mix' dye 
was added to the mixture and electrophoresed on 1% agarose for 2 hr at 30 mA in TAE 
buffer, pH 7.9. The gels were stained with ethidium bromide (0.5^g/ml), visualized under 
UV light and photographed. 
(c) Enzyme linked immunosorbent assay 
The following reagents were prepared in distilled water and used in enzyme 
immunoassay. 
(i) Buffers and reagents 
Tris buffered saline (TBS) 
10 mM Tris, 150 mM NaCl, pH 7.4 
Tris buffered salinc-Tween 20 (TBS-T) 
20 mM Tris, 144 mM NaCl, 2.68 mM KCl 
pH 7.4, containing 500 |il Tween 20/L. 
Carbonate-bicarbonate buffer 
15 mM sodium carbonate, 35 mM sodium bicarbonate, pH 9.6, containing 2 mM 
magnesium chloride. 
Substrate 
500 i^g p-nitrophenyl phosphate/ml of carbonate-bicarbonate buffer, pH 9.6. 
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(i) Procedure 
Antibodies were detected by ELISA using polystyrene microtitre plates as solid 
support (Aotsuka et ai, 1979). One hundred microlitre of 2.5 |ag/ml antigen in TBS, pH 
7.4 was coated in test wells of microtitre plates, incubated for 2 hr at 37°C and overnight 
at 4°C. The antigen coated wells were washed three times with TBS-T to remove 
unbound antigen. Unoccupied sites were blocked with 150 |J1 of 1.5% BSA in TBS for 
4 - 5 hrs at room temperature. The plates were washed once with TBS-T and antibody 
(100 fxl/wdl) to be tested, diluted in TBS was added to each well. After 2 hr incubation a( 
37°C and overnight at 4°C, the plates were washed four times with TBS-T and an 
appropriate anti-immunoglobulin alkaline phosphatase conjugate was added to each well. 
After incubation at 37°C for 2 hr, the plates were washed four times with TBS-T and 
three times with distilled water and developed using p-nitrophenyl phosphate substrate 
respectively. The absorbance was recorded at 410 nm on an automatic microplate reader. 
Each sample was run in duplicate. The control wells were treated similarly but were 
devoid of antigen. Results were expressed as a mean of Afest - Acontroi-
Competition ELISA 
The antigenic specificity of the antibodies was determined by competition ELISA 
(Hasan et al., 1991). Varying amount of inhibitors (0-20 |ag/ml) were mixed with a 
constant amount of antiserum or IgG. The mixture was incubated at room temperature for 
2 hr and overnight at 4°C. The immune complex thus formed was coated in the wells 
instead of the serum. The remaining steps were the same as in direct binding ELISA. 
Percent inhibition was calculated using the formula 
Percent inhibition = 1 ^!^^!^!i^ x 1 0 0 
A 
uninhibited 
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Purification and Fragmentation of Calf Thymus DNA 
Commercially available calf thymus DNA was purified free of proteins and single 
stranded regions and digested with micrococcal nuclease to obtain fragments, which were 
separated by chromatography on Sepharose 4B column. The size of DNA fragments was 
analyzed on 7.5% PAGE, using 100 bp ladder as DNA molecular weight marker (Fig. 2). 
Fragments of approximately 400 bp were used for further studies. The 400 bp DNA 
fragments would be referred as DNA. 
Isolation and Purification of Plasmid Bluescript DHsa "KS" 
Plasmid Bluescript (pBS) was isolated from E.coli strain DH5a using alkaline 
extraction method (Maniatis et al., 1989). The isolated plasmid was cesium chloride 
purified to obtain the supercoiled (SC) form. The isolated DNA was subjected to agarose 
gel electrophoresis (Fig. 3). The lower band is the supercoiled form whereas the upper 
bands show the linear and open circular form. 
Modification of DNA Fragments by Hydroxyl Radical 
400 bp (approximate size) calf thymus DNA was modified with hydroxyl radical 
generated by UV irradiation (254 nm) in presence of hydrogen peroxide. The modified 
samples (ROS-DNA) were dialyzed extensively against PBS, pH 7.4 to remove excess 
hydrogen peroxide. 
The UV absorption spectra of ROS-DNA revealed a marked hypochromicity at 
260 nm. The corresponding controls i.e. DNA treated with hydrogen peroxide (without 
UV irradiation) or DNA treated with UV irradiation alone showed no appreciable change 
in their UV absorption characteristics (Fig. 4). 
Thermally induced transitions were measured spectrophotometrically at 260 nm 
by heating nucleic acid samples at a rate of 1.5°C/min. Melting curves were obtained at 
temperature from 30°C to 95 °C. The increase in absorbance at 260 nm was taken as a 
measure of denaturation. The process was characterized by determining the percent DNA 
in denatured state as a function of temperature. The melting temperature (Tm) of native 
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Fig. 2. Elution profile of micrococcal nuclease digested calf thymus DNA on 
Sepharose 4B column. Inset: Polyacrylamide gel electrophoresis of 
fractionated DNA. Lanes (3-10) represent alternate fractions from 30-4^ 
while lanes 1 contained 100 bp DNA ladder as marker. 
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Fig. 3. Agarose gel electrophoretic pattern of isolated plasmid Bluescript DHsa "KS" 
Electrophoresis was performed on 1% agarose gel at 30 mA for 2 hr. The 
amount of DNA used was 0.5 }ig. 
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Fig. 4. UV absorption spectra of native DNA and ROS-DNA. Native DNA (—), UV 
irradiated DNA (- - ) , DNA-hydrogen peroxide complex (-•- ) and ROS-
DNA (—). 
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DNA at which 50% of the double helical structure is lost was found to be 88°C, while in 
case of ROS-DNA it was found to be 78°C (Fig. 5). The results exhibit a net decrease of 
10°C in the Tm value for the modified DNA when compared to its unmodified native 
conformer. The findings point out structural alterations in DNA and a partial destruction 
of the secondary structure of DNA on interaction with ROS. The UV absorption and 
thermal denaturation characteristics of native and ROS-DNA are listed in Table 3. 
ROS-modified and unmodified DNA was digested with nuclease S1 (20 units/|ig 
DNA) and resolved by agarose gel electrophoresis (Fig. 6). The controls were native and 
ROS-DNA untreated with SI. Nuclease SI treated ROS-DNA showed almost total 
digestion after 30 min of incubation, while native DNA remained undigested. Hydrogen 
peroxide in the presence of UV light therefore created sufficient structural alterations in 
DNA to be a substrate for single strand specific nuclease S1. 
Nucleic acids with different secondary structures have more affinity for 
hydroxyapatite than flexible disordered polymers. To ascertain the double strandedness 
of ROS-DNA, native and modified DNA samples were fractionated in hydroxyapatite 
column. The DNA samples (native and ROS-modified) in 10 mM sodium phosphate 
buffer, pH 6.8, were applied to hydroxyapatite column, equilibrated with the same buffer. 
After washing the unbound material, batch elution was carried out with 125 mM and 
250 mM Na-K-phosphate buffer, pH 6.8. Three ml fractions were collected and 
absorbance was monitored at 260 nm. The chromatographic profile (Fig. 7), showed 
elution of native DNA as a single peak at 250 mM Na-K-phosphate buffer, pH 6.8, 
whereas, the elution profile of ROS-DNA exhibited two distinct peaks, a minor and a 
major peak eluting with 125 mM and 250 mM Na-K-phosphate buffer, pH 6.8. 
respectively, accompanied by a slight shift in peak position. 
Modification of Plasmid DNA by Hydroxyl Radical 
Plasmid DNA was modified with reactive oxygen species (ROS) generated by the 
UV irradiation (254 nm) in the presence of hydrogen peroxide. The modified samples 
were dialyzed extensively against PBS, pH 7.4 to remove excess hydrogen peroxide. 
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Fig. 5. Thermal denaturation profile of native DNA (O) and ROS-DNA (•). 
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TABLE - 3 
UV Absorption and Thermal Denaturation Characteristics of Native 
and ROS-Modified DNA 
Parameter Native DNA 
1.8 
27.5 
88 
70 
ROS-DNA 
1.5 
19.5 
78 
45 
Absorbance ratio (A260/A280) 
Percent hyperchromicity at 95 °C 
Melting temperature (Tm), °C 
Onset of duplex melting, °C 
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i 3 ^ 
Fig. 6. Nuclease SI digestibility of native and ROS-DNA. Lane 1 contained native 
DNA, while lane 2 contained native DNA treated with nuclease SI. Lane 3 
contained ROS-DNA, while lane 4 contained ROS-DNA treated with SI for 
30 min. Electrophoresis was carried out on 1% agarose for 2 hr at 30 mA. 
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Fig. 7. Hydroxyapatite column chromatography of native DNA (a) and ROS-DNA (b). 
Batch elution was carried out with 125 mM and 250 mM sodium potassium 
phosphate buffer, pH 6.8. 
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Characterization of ROS-plasmid DNA 
Figure 8 shows UV absorption spectra of native and ROS modified plasmid DNA. 
The UV spectra of ROS-plasmid DNA revealed a marked hypochromicity (27%) at 
260 nm. 
Generation of OH radical was confirmed using mannitol, a quencher of OH 
radical. Calf thymus DNA fragments were modified in the absence and presence of two 
different concentrations of mannitol (75 mM and 150 mM). Figure 9 shows a marked 
hypochromicity of DNA sample in the absence of mannitol, whereas the hypochromicity 
was to a lesser extent in the presence of mannitol. However the change was more 
pronounced at a concentration of 150 mM than 75 mM. 
Plasmid DNA was modified in presence and absence of mannitol. Figure 10 
shows UV absorption spectra of native plasmid DNA, ROS-plasmid DNA and ROS-
plasmid DNA in presence of 150mM mannitol. Less damage was observed in presence of 
mannitol whereas damage in absence of marmitol was to a greater extent. 
Fluorescence spectra of native and ROS-plasmid DNA was taken using ethidium 
bromide (Fig. 11). A decrease in the fluorescence intensity was seen in case of ROS-
plasmid DNA as compared to its native form. Partial destruction of the helical structure 
of DNA due to ROS modification may attribute to the decrease in fluorescence intensity. 
Agarose Gel Electrophoresis 
The strand breaks (both single and double) induced in ROS-modified plasmid 
DNA were fiirther confirmed by agarose gel electrophoresis. Both native plasmid and 
ROS-plasmid DNA were run on 1% agarose (Fig. 12). The supercoiled form has 
completely disappeared whereas there is an increase in fluorescence in the linear form in 
case of ROS-plasmid DNA. These changes can be attributed to the conversion of 
supercoiled form of plasmid to linear form due to strand breaks caused by hydroxy! 
radical. 
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Fig. 9. UV absorption spectra of calf thymus DNA modified by hydroxyl radical in 
absence and presence of two concentrations of mannitol. Native DNA ( ). 
ROS-DNA (•••••), ROS-DNA with 75 mM mannitol ( ) and ROS-DNA 
with 150 mM mannitol (—). 
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Fig. 10. UV-absoq)tion spectra of plasmid DNA modified by hydroxyl radical in 
absence and presence of mannitol, a specific quencher of hydroxyl radical. 
Native plasmid DNA ( ), ROS-plasmid DNA ( ) and ROS plasmid 
DNA modified in presence of mannitol (-•-). 
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Fig. 12. Agarose gel electrophoresis of native plasmid (Lane 1) and ROS-plasmid 
DNA (Lane 2). Electrophoresis was carried out on 1% agarose gel for 2 hr at 
30 mA. 
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Nuclease SI Digestibility of ROS-Modified DNA 
Native and ROS-modified plasmid DNA were digested with nuclease SI (0.5 
units/^g DNA). The residual DNA was detected by agarose gel electrophoresis. The 
controls were the unmodified DNA samples with and without nuclease SI treatment. The 
result showed low intensity of linear form, which also appeared as diffused band. Native 
DNA and nuclease SI treated native DNA showed almost identical electrophoretic 
migration pattem and fluorescence intensity (Fig. 13). 
EcoRI Digestion of Native and ROS-plasmid DNA 
Both native and ROS-plasmid DNA were treated with equal units of EcoRI (Fig. 
14). In case of native DNA, a band corresponding to linear form is seen upon digestion. 
Since EcoRI has a single site on pBS, it linearised the plasmid. However no change is 
seen in case of EcoRI digestion of ROS-plasmid DNA. 
Immunogenicity of ROS-Modified Plasmid DNA 
The antigenicity of modified plasmid DNA was determined by inducing 
antibodies in rabbits. The antigenic specificity of the induced antibodies was assayed by 
direct binding and competition ELISA. The binding of these antibodies to the 
immunogen and native plasmid DNA was further substantiated by band shift assay. 
Antibodies Against ROS-Modified DNA 
The antibodies raised against ROS-modified DNA was fovmd to be non 
precipitating as observed by immunodiffusion. Direct binding ELISA on plates coated 
with ROS-modified plasmid DNA indicated a high binding activity with different serum 
dilutions showing a titre of >1:12800 (Fig. 15). Preimmune serum did not show 
appreciable binding with the immunogen. 
The specificity of anti-ROS-plasmid DNA antibodies for epitopes on immunogen 
was evaluated by competitive ELISA. A maximum of 70% inhibition in antibody binding 
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Fig. 13. Nuclease SI digestibility of native and ROS-plasmid DNA. Lane 1 contained 
native plasmid DNA, while lane 2 contained native plasmid DNA treated with 
nuclease SI. Lane 3 contained ROS-plasmid DNA while Lane 4 contained 
ROS-plasmid DNA treated with nuclease SI for 30 min. Electrophoresis was 
carried out on 1% agarose for 2 hr at 30 mA. 
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Fig. 14. Eco RI digestion of native plasmid and ROS-plasmid DNA. Lane 1 contained 
native plasmid DNA, lane 2 contained native plasmid DNA treated with 
EcoRI, lane 3 contained ROS-plasmid DNA while lane 4 contained EcoRI 
treated ROS-plasmid DNA. Electrophoresis was performed on 1% agarose gel 
for 2 hr at 30 mA. The amount of DNA used for electrophoresis was Ifag. 
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Fig. 15. Level of induced antibodies against ROS-plasmid DNA. Direct binding 
ELISA with preimmune serum (A) and immune serum (A). The microtitre 
plate was coated with ROS-plasmid DNA (2.5 |^g/ml). 
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was recorded at an inhibitor (ROS-modified plasmid DNA) concentration of 20 i^g/ml 
(Fig. 16). Tiie concentration of the competitor required for 50% inhibition was 2.5 |ag/ml. 
Purification and Binding Characteristics of Immune IgG 
Immunoglobulin G was isolated from pre-immune and immune rabbit serum by 
affinity chromatography on Protein-A agarose column (Fig. 17). The purity of the IgG 
was ascertained by SDS-polyacrylamide gel electrophoresis under non-reducing 
conditions (Fig. 17, Inset). The purified IgG migrated as single band. 
Direct binding ELISA of the purified IgG showed a strong binding with the 
immunogen (Fig. 18). Preimmime IgG as control showed negligible binding to ROS-
modified DNA. The specificity of the purified IgG was evaluated by competitive 
inhibition assay. A maximum of 86% inhibition of anti-ROS plasmid DNA IgG binding 
to immunogen was observed (Fig. 19). Fifty percent inhibition was achieved at an 
inhibitor concentration of 1.6 |ig/ml. 
Immuno-crossreactivity of Anti-ROS-Plasmid DNA Antibodies 
The antigenic specificity of the induced anti-ROS-plasmid DNA antibodies was 
characterized by competition inhibition assay. The anti-ROS-plasmid DNA antibodies 
exhibited a wide range of heterogeneity as demonstrated by inhibition assays, using the 
immunogen, nucleic acid polymers, and synthetic polynucleotides as inhibitors. A 
maximum of 86% inhibition of the anti-ROS-plasmid DNA IgG with the immunogen as 
an inhibitor was observed (Fig. 19). Competition experiments with native DNA showed 
considerable inhibition in antibody activity. Preincubation of immune antibody with 
native plasmid DNA inhibited its binding to modified DNA by 38% at 20 ^g/mi 
(Fig. 19). Human DNA and 400 bp fragments of calf thymus DNA showed moderate 
inhibition of 31% and 25%, respectively (Fig. 20) whereas their ROS modified 
conformers were inhibitory to the extent of 65.4% and 61% respectively. O r modified 
DNA and chromatin showed an inhibition of 34% and 18% respectively. In addition 
cardiolipin and chondroitin sulphate were also inhibitory to the antibody activity, 
showing an inhibition of 39% and 33%, respectively (Fig. 21). 
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Fig. 16. Inhibition ELISA of immune (A) and preimmune senun (A) against ROS-
plasmid DNA. ROS plasmid DNA was used as an inhibitor. The microtitre 
plate was coated with ROS- plasmid DNA (2.5 )ig/ml) 
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Fig. 17. Elution profile of anti-ROS-plasmid DNA IgG on Protein A-Agarose column. 
Inset: SDS-PAGE of purified IgG on 7.5% polyacrylamide gel. 
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Fig. 18. Binding of affinity purified preimmune (A) and immune IgG (A) to ROS-
plasmid DNA. The microtitre plates were coated with ROS-plasmid DNA 
(2.5 i^g/ml). 
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Fig. 19. Inhibition of anti-ROS-plasmid DNA IgG binding to ROS-plasmid DNA. The 
inhibitors were ROS-plasmid DNA (A) and native plasmid DNA (A). The 
microtitre plates were coated with ROS-plasmid DNA (2.5 f^g/ml). 
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Fig. 20. Inhibition of anti-ROS-plasmid DNA IgG binding to ROS-plasmid DNA. The 
competitors were native 400 bp DNA (A), ROS-400 bp DNA (A), native 
human DNA (O) and ROS-human DNA (•). The microtitre plates were 
coated with ROS-plasmid DNA (2.5 Mg/ml). 
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Fig. 21. Inhibition of anti-ROS-plasmid DNA IgG binding to ROS-plasmid DNA. The 
competitors were 0*2* DNA (A), chromatin (A), cardioHpin (O) and 
chondroitin sulphate (•). The microtitre plates were coated with ROS-plasmid 
DNA (2.5 i^g/ml). 
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Adenine, thymine and their ROS-modified forms were used as inhibitors of 
antibody activity. Adenine, ROS-adenine and thymine were non-inhibitory showing 
inhibitions of 14%, 20.2% and 29.5% respectively. In contrast ROS-thymine was a better 
inhibitor showing a maximum inhibition of 51% (Fig. 22). 
Among the synthetic polymers, poly(dA-dT).poly(dA-dT) showed a maximum 
inhibition of 64.4% at 20 |ag/ml whereas poly(dA-dU).poIy(dA-dU) and poly(dI-dC).poly 
(dl-dC) were poor inhibitors of antibody activity showing an inhibition of 3.2% and 
18.3%, respectively (Fig. 23). Table 4 summarizes the data of the binding characteristics 
of anti-ROS-plasmid DNA IgG as determined by inhibition ELISA. 
Band Shift Assay 
In order to check the working conditions of band shift assay, human serum 
albumin (HSA) and anti-HSA IgG were used. With normal human IgG, the formation of 
immune complex was negligible. Similar was the case with preimmune rabbit IgG 
(Fig. 24a). However, the immune complex formation was evident with anti-HSA IgG. 
Varying amount of immune anti-HSA IgG was used with a constant amount of HSA. 
Figure 24b shows, that with the increase in IgG concentration there is increased immune 
complex formation and thereby decrease in the mobility of HSA. 
The visual detection of binding of 400 bp calf thymus DNA, native plasmid DNA 
and ROS-plasmid DNA to the anti-ROS-plasmid DNA IgG was ascertained by band shift 
assay (Figs. 25-27). Constant amount of DNA in each case was incubated with varying 
amounts of anti-ROS-plasmid DNA IgG for 2 hr at room temperature and overnight at 
4°C. The resulting immune complexes were then electrophoresed on 1% agarose for 2 hr 
at 30 mA. The immune complex formation in case of 400 bp and native plasmid DNA 
was negligible (Figs. 25,26). However in case of ROS-plasmid DNA, with the increase in 
the amount of IgG, there was an increase the formation of high molecular weight immune 
complexes, which resulted in retarded mobility and decrease in intensity of the unbound 
ROS-plasmid DNA (Fig. 27). This shows the specificity of the antibodies towards the 
immunogen. 
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Fig. 22. Inhibition of anti-ROS-plasmid DNA IgG binding to ROS-plasmid DNA. Tlie 
competitors were thymine (A), ROS-thymine (A), adenine (O) and ROS-
adenine (•). The microtitre plates were coated with ROS-plasmid DNA 
(2.5 Mg/ml). 
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Fig. 23. Inhibition of anti-ROS-plasmid DNA IgG binding to ROS-plasmid DNA. The 
competitors were poly(dA-dT).poly(dA-dT) (O), poly(dI-dC).poly(dI-dC) 
(A) and poly(dA-dU).poly (dA-aU) (A). The microtitre plates were coated 
with ROS-plasmid DNA (2.5 |ig/ml). 
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TABLE - 4 
Antigenic Binding Specificity of Anti-ROS-Plasmid DNA Antibodies 
Inhibitor Maximum % inhibition at 20 ^g/ml 
Native plasmid DNA 38 
ROS-plasmid DNA 86 
Native 400 bp DNA 25 
ROS-400bpDNA 61 
Native human DNA 31 
ROS-human DNA 65.4 
02'"DNA 34 
Chromatin 18 
Chondroitin sulphate 33 
Cardiolipin 39 
Thymine 29.5 
ROS-thymine 51 
Adenine 14 
ROS-adenine 20.2 
Poly(dA-dT).poly(dA-dT) 66.4 
Poly(dI-dC).poly(dI-dC) 18.3 
Poly(dA-dU).poly(dA-dU) 3.2 
The microtitre plates were coated with ROS-plasmid DNA (2.5 ng/ml). 
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Fig. 24. (a) Band shift assay of human serum albumin (HSA) with normal human IgG 
and preimmune rabbit IgG. Lane 1 contained HSA, lane 2 contained anti-
human IgG, lane 3 contained immune complex of HSA with normal human 
IgG, lane 4 contained immune complex of HSA with preimmune rabbit IgG 
while lane 5 contained immune complex of HSA and anti-HSA IgG. 7.5% 
polyacrylamide gel with 2.5% stacking was run at 50 volts for 3 hr. 
(b) Band shift assay of human serum albumin (HSA) with increasing 
concentration of anti-HSA IgG. HSA (30 ^g) was incubated with buffer (lane 
1) and 30,60,90, and 120 jig of IgG through lanes 2 to 5 respectively for 2 hr 
at 37°C and overnight at 4°C. Lane 6 contained anti-HSA IgG. 7.5% 
polyacrylamide gel with 2.5% stacking was run at 50 volts for 3 hr. 
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Fig. 25. Band shift assay of anti-ROS-plasmid DNA IgG binding to native 400 bp calf 
thymus DNA. Native 400 bp DNA (1 ^g) was incubated with 10,20,40 and 80 
|xg IgG for 2 hr at 37°C and overnight at 4°C. Electrophoresis was performed 
on 1% agarose for 2 hr at 37°C. Lane 1 contained native 400 bp DNA, while 
lane 2 to 5 contained native 400 bp DNA with increasing concentrations of 
IgG. 
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Fig. 26. Band shift assay of anti-ROS-plasmid DNA IgG binding to native plasmid 
DNA. Native plasmid DNA (0.5 ^g each) was incubated with buffer and 10, 
20, 40 and 80 ^g IgG for 2 hr at 37°C and overnight at 4°C. Electrophoresis 
was performed on 1% agarose for 2 hr at 37°C. Lane 1 contained native 
plasmid DNA, while lane 2 to 5 contained native plasmid DNA with 
increasing concentrations of IgG. 
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Fig. 27. Band shift assay of anti-ROS-plasmid DNA IgG binding to ROS-plasmid 
DNA. ROS-plasmid DNA (0.5 ^g each) was incubated with buffer (lane !) 
and 10,20,40,80 ^g IgG through lanes 2 to 5 respectively for 2 hr at 37°C and 
overnight at 4°C. Electrophoresis was performed on 1% agarose gel for 2 hr at 
30 mA. 
Binding Characteristics of Circulating Human Anti-DNA Auto-
antibodies to ROS-Plasmid DNA 
Various SLE serum samples were tested for the presence of anti-DNA antibodies 
by direct binding ELISA. Binding of 24 SLE sera (1:100 dilution) to native calf thymus 
DNA, native plasmid DNA and ROS-plasmid DNA were assayed by direct binding 
ELISA (Figs. 28. 29). All the sera showed greater reactivity towards ROS-plasmid DNA 
whereas native plasmid DNA and native calf thymus DNA showed almost similar 
binding. 
Antigenic Specificity of SLE Autoantibodies 
The specificity of each SLE serum for native and ROS-plasmid DNA was 
evaluated by competitive binding assay (Figs. 30-41). The antibody was incubated with 
increasing concentrations (0-20 |ig/ml) of inhibitors (native or ROS-plasmid DNA). Out 
of the 24 SLE sera tested, ROS-plasmid DNA showed higher degree of recognition to 23 
sera and inhibited their activity to a maximum of 71% and 50% inhibition was achieved 
in 20 samples. On the other hand, native plasmid DNA was found to be less reactive for 
the same samples showing a maximum of 48% inhibition. However one sample showed 
almost similar recognition towards native plasmid DNA, showing inhibition of 46% in 
both the cases. 
The results of this study, summarized in Table 5 show ROS-plasmid DNA to be a 
better inhibitor for all the 24 SLE sera tested. 
Purification of SLE IgG 
Protein A binds IgG from most mammalian species through interactions with the 
Fc part of the IgG molecules. SLE IgG were purified by affinity chromatography on 
Protein-A agarose column. The purified IgG eluted in a single symmetrical peak 
(Fig. 42). Purity of IgG was checked by SDS-PAGE under non-reducing conditions. The 
purified IgG migrated as a single band (Fig. 42, Inset). 
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Fig. 28. Direct binding ELISA of human SLE anti-DNA autoantibodies to native calf 
thymus DNA (jm), native plasmid DNA ( ^ ) and ROS-plasmid DNA ( ^ ) 
Microtitre plates were coated with 2.5 ^g/ml of respective antigens. 
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Fig. 29. Direct binding ELISA of human SLE anti-DNA autoantibodies to native calf 
thymus DNA ( ^ ) , native plasmid DNA ('m) and ROS-plasmid DNA (m)-
Microtitre plates were coated with 2.5 ^g/ml of respective antigens. 
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Fig. 30. Inhibition of SLE anti-DNA autoantibodies from SLE sera (1 and 2). The 
inhibitors used were native plasmid DNA (A,0) and ROS-plasmid DNA 
(A,«). The microtitre plates were coated with ROS-plasmid DNA (2.5 fig/ml). 
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Fig. 31. Inhibition of SLE anti-DNA autoantibodies from SLE sera (3 and 4). The 
inhibitors used were native plasmid DNA (A,0) and ROS-plasmid DNA 
(A,«). The microtitre plates were coated with ROS-plasmid DNA (2.5 ^g/nil). 
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Fig. 32. Inhibition of SLE anti-DNA autoantibodies from SLE sera (5 and 6). The 
inhibitors used were native plasmid DNA (A,0) and ROS-plasmid DNA 
(A,»). The microtitre plates were coated with ROS-plasmid DNA (2.5 |ag/ml). 
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Fig. 33. Inhibition of SLE anti-DNA autoantibodies from SLE sera (7 and 8). The 
inhibitors used were native plasmid DNA (A,0) and ROS-plasmid DNA 
(A,«). The microtitre plates were coated with ROS-plasmid DNA (2.5 Hg/m\). 
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Fig. 34. Inhibition of SLE anti-DNA autoantibodies from SLE sera (9 and 10). The 
inhibitors used were native plasmid DNA (A,0) and ROS-plasmid DNA 
(A,»). The microtitre plates were coated with ROS-plasmid DNA (2.5 |ug/ml). 
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Fig. 35. Inhibition of SLE anti-DNA autoantibodies from SLE sera (11 and 12). Ihe 
inhibitors used were native plasmid DNA (A,0) and ROS-plasmid DNA 
(A,»). The microtitre plates were coated with ROS-plasmid DNA (2.5 ^g/ml). 
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Fig. 36. Inhibition of SLE anti-DNA autoantibodies from SLE sera (23 and 14). Tlie 
inhibitors used were native plasmid DNA (A,0) and ROS-pIasmid DNA 
(A,»). The microtitre plates were coated with ROS-plasmid DNA (2.5 )ig/nil). 
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Fig. 37. Inhibition of SLE anti-DNA autoantibodies from SLE sera (15 and 16). The 
inhibitors used were native plasmid DNA (A,0) and ROS-plasmid DNA 
(A,»). The microtitre plates were coated with ROS-plasmid DNA (2.5 ^g/nil). 
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Fig. 38. Inhibition of SLE anti-DNA autoantibodies from SLE sera (17 and 18). Tlie 
inhibitors used were native plasmid DNA (A,0) and ROS-plasmid DNA 
(A,«). The microtitre plates were coated with ROS-plasmid DNA (2.5 ^g/ml). 
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Fig. 39. Inhibition of SLE anti-DNA autoantibodies from SLE sera (19 and 20). The 
inhibitors used were native plasmid DNA (A,0) and ROS-plasmid DNA 
(A,»). The microtitre plates were coated with ROS-piasmid DNA (2.5 /Jg/ml). 
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Fig. 40. Inhibition of SLE anti-DNA autoantibodies from SLE sera (21 and 22). The 
inhibitors used were native plasmid DNA (A,0) and ROS-plasmid DNA 
(A,«). The microtitre plates were coated with ROS-plasmid DNA (2.5 jJg/ml). 
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Fig. 41. Inhibition of SLE anti-DNA autoantibodies from SLE sera (23 and 24). The 
inhibitors used were native plasmid DNA (A,0) and ROS-plasmid DNA 
(A,«). The microtitre plates were coated with ROS-plasmid DNA (2.5 |ig/ml). 
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TABLE - 5 
Competitive Inhibition Data of SLE Sera 
Serum No. Maximum percent inhibition at (20 ^g/ml) 
Native plasmid DNA ROS-plasmid DNA 
1 39.4 57.1 
2 32 60 
3 30 46 
4 41.8 71 
5 36 50.4 
6 29.2 70.5 
7 42 56 
8 32.5 68.3 
9 44 59 
10 30.4 55 
11 38.2 54 
12 48.2 52 
13 40.2 56 
14 29 50 
15 26.4 63.3 
16 34 68 
17 34 68 
18 22.6 42.1 
19 44 61 
20 25 56 
21 42.5 64.5 
22 28.1 40.2 
23 46.4 45.7 
24 38.2 66 
Microtitre plates were coated with ROS-plasmid DNA (2.5 \igfml). 
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Fig. 42. Elution profile of SLE IgG on Protein A-Agarose column. Inset: SDS-PAGE 
of purified IgG on 7.5% polyacrylamide gel. 
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Band Shift Assay Using SLE IgG 
Band shift assay was employed to visualize and confirm the interaction of native 
and ROS-plasmid DNA with SLE autoantibodies. A constant amount of antigen was 
incubated with increasing amounts (0-100 ^g) of SLE IgG for 2 hr at 37°C and overnight 
at 4°C. The immune complexes were then electrophoresed on 1% agarose for 2 hr at 30 
mA. Figure 43 and 44 shows the binding of anti-DNA autoantibodies to native and ROS-
plasmid DNA respectively. With increasing concentration of IgG there is a corresponding 
increase in the formation of high molecular weight immune complexes which resulted in 
retarded mobility and corresponding decrease in the fluorescence intensity of the 
unbound antigen. 
Detection of Antibodies to Native and ROS-plasmid DNA in Cancer 
Sera 
The study comprised of 29 samples of sera from patients suffering from cancer of 
different organs/organ systems. Sera from normal, healthy individuals served as controls. 
Cancer sera were obtained after careful clinical examination of patients with proven 
histopathological diagnosis attending J.N. Medical College Hospital, A.M.U., Aligarh. 
The binding of circulating antibodies in cancer sera (at 1:100 dilution) with native 
and ROS-plasmid DNA was assessed by direct binding ELISA. All the sera showed 
higher recognition to ROS-plasmid DNA (Fig. 45). 
The reactivity of serum antibodies to native and ROS-DNA was studied by 
competitive ELISA. Out of the 29 samples collected, four sera were from patients with 
breast cancer (Fig. 46). All these four szimples showed higher recognition towards ROS-
plasmid DNA than native plasmid DNA. The maximum, inhibition in antibody reactivity 
achieved by ROS-plasmid DNA was greater (55%, 56.6%, 52.1%, 34%) than native 
plasmid DNA (33.2%, 25%, 31.8%, 21.7%), respectively. 
Four sera from patients of head and neck carcinoma (Fig. 47) were studied. All of 
these were found to recognize ROS-plasmid DNA to a greater extent (68.5%, 55%, 35%, 
54.9%) than native plasmid DNA (46%, 29.9%, 22%, 26.8%), respectively. 
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Fig. 43. Band shift assay of SLE IgG binding to native plasmid DNA. Native plasmid 
DNA (0.5 i^g each) was incubated with buffer (lane 1) and 25, 50, 75 and 100 
^g IgG through lanes 2 to 5 respectively for 2 hr at 37°C and overnight at 4°C. 
Electrophoresis was performed on 1% agarose for 2 hr at 30 mA. 
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Fig. 44. Band shift assay of SLE IgG binding to ROS-pIasmid DNA. ROS-plasmid 
DNA (0.5 tag each) was incubated with buffer (lane 1) and 25, 50, 75 and 100 
|ig IgG through lanes 2 to 5 respectively for 2 hr at 37°C and overnight at 4°C. 
Electrophoresis was performed on 1% agarose for 2 hr at 30 mA. 
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Fig. 45. Binding of various cancer sera to native (•) and ROS-plasmid DNA (S) 
Normal human sera serve as negative control. The histogram shows mean 
absorbance values for binding of NHS and sera from patients with cancer of 
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Fig. 46. Detection of antibodies against native and ROS-plasmid DNA, in the sera of 
patients with cancer of breast (a) Cancer sera 1 and 2 by native plasmid DNA 
(A,0) and ROS-plasmid DNA (A,«), (b) Cancer sera 3 and 4 with native 
plasmid DNA (A,0) and ROS-plasmid DNA (A,0). The microtitre plates 
were coated with ROS-plasmid DNA (2.5 |ig/ml). 
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Fig. 47. Detection of antibodies against native and ROS-plasmid DNA, in the sera of 
patients with cancer of head and neck (a) Cancer sera 1 and 2 by native 
plasmid DNA (A,0) and ROS-plasmid DNA (A,#), (b) Cancer 3 and 4 with 
native plasmid DNA (A,0) and ROS-plasmid DNA (A,»). The microtitrc 
plates were coated with ROS-plasmid DNA (2.5 |ag/ml). 
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Six samples were from patients with oral cancer (Fig. 48). All of these showed 
higher recognition towards ROS-plasmid DNA (56%, 52%, 47%, 53% 37%, 57.8%), 
whereas native plasmid DNA was recognized to a lesser extent (45%, 30.1%, 26.7%, 
39%, 26.6%, 32.3%), respectively. 
Among the four sera collected from patients with carcinoma of prostrate, all were 
found to be more reactive towards ROS-plasmid DNA (54.3%, 50.8%, 46.9% and 42.5%) 
than the native plasmid DNA (33.4%, 36.5% 30.7% and 23.7%), respectively (Fig. 49). 
Of the four samples collected from gall bladder patients, the binding towards 
native plasmid DNA was lesser (43.6%, 27.3%, 30.3% and 23.0%) than the ROS-plasmid 
DNA (50.2%, 45%, 47% and 42.2%), respectively (Fig. 50). 
Among the three samples from patients with lung cancer (Fig. 51), two showed 
greater reactivity towards ROS-plasmid DNA (44.2% and 37.2%) than to its native form 
(27% and 18.5%). while one sample showed higher recognition to native plasmid DNA 
(42.8%) compared to ROS-plasmid DNA (36.5%). 
The group of patients with miscellaneous cancers comprised of two patients with 
cancer of vulva whereas one patient each of Hodgkin's lymphoma and CML (Fig. 52). 
Maximum percent inhibition of serum from these patients, achieved by ROS-plasmid 
DNA was 47.3%, 50%, 45.9% and 40.3% respectively. Native plasmid DNA was 
inhibitor)' to a lesser extent, showing maximum inhibition of 26%, 36.8%), 27% and 
26.2% respectively. These results have been summerised in Table 6. 
Band Shift Assay Using Cancer IgG 
Band shift assay of native and ROS-plasmid DNA was performed using IgG of 
head and neck cancer patient (Fig. 53). Constant amount of antigen was incubated with 
increasing concentration of cancer IgG (0-120 ^g). The immune complexes were 
incubated at 37°C for 2 hr and overnight at 4''C. The samples were electrophoresed on 
1% agarose at 30 mA. Figure 54 and 55 shows the binding of cancer IgG to native and 
ROS-plasmid DNA. With the increase in IgG concentration there is a reduction in the 
mobility and fluorescence intensity of the unbound antigen. In case of ROS-plasmid 
DNA, the retardation is much greater as compared to the native form. 
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Fig. 48. Detection of antibodies against native and ROS-plasmid DNA, in the sera of 
patients with cancer of oral cavity (a) Cancer sera 1,2 and 3 by native plasmid 
DNA (A.O.D) and ROS-plasmid DNA (A,»,B), (b) Cancer sera 4,5 and 6 
with native plasmid DNA (A,0,D) and ROS-plasmid DNA (A,»,B). The 
microtitre plates were coated with ROS-plasmid DNA (2.5 |j.g/ml). 
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Fig. 49. Detection of antibodies against native and ROS-plasmid DNA, in the sera of 
patients with cancer of prostrate (a) Cancer sera 1 and 2 by native plasmid 
DNA (A,0) and ROS-plasmid DNA (A,»), (b) Cancer sera 3 and 4 with 
native plasmid DNA (A,0) and ROS-plasmid DNA (A,«). The microtitre 
plates were coated with ROS-plasmid DNA (2.5 ^g/ml). 
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Fig. 50. Detection of antibodies against native and ROS-plasmid DNA, in the sera of 
patients with cancer of gall bladder (a) Cancer sera 1 and 2 by native plasmid 
DNA (A,0) and ROS-plasmid DNA (A,»), (b) Cancer sera 3 and 4 with 
native plasmid DNA (A,0) and ROS-plasmid DNA (A,«). The microtitre 
plates were coated with ROS-plasmid DNA (2.5 ^g/ml). 
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Fig. 51. Detection of antibodies against native and ROS-plasmid DNA, in the sera of 
patients with cancer of lung (a) Cancer sera 1 and 2 by native plasmid DNA 
(A,0) and ROS-plasmid DNA (A,«), (b) Cancer sera 3 with native plasmid 
DNA (A) and ROS-plasmid DNA (A.). The microtitre plates were coated with 
ROS-plasmid DNA (2.5 ^g/ml). 
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Fig. 52. Detection of antibodies against native and ROS-plasmid DNA, in the sera of 
patients with cancer of vulva, Hodgkin's lymphoma and CML. (a) Cancer of 
vulva (sera 1 and 2) with native plasmid DNA (A,0) and ROS-plasmid DNA 
(A,«), (b) cancer of Hodgkin's lymphoma and CML with native plasmid 
DNA (A,0) and ROS-plasmid DNA (A,«). 
TABLE- 6 
Inhibition of Circulating Antibodies in Cancer Sera with Native and 
ROS-plasmid DNA 
Type of cancer 
Breast 
Head and neck 
Oral 
Prostrate 
Gall bladder 
Lung 
Vulva 
Hodgkin's 
lymphoma 
CML 
No. of sera 
tested 
4 
4 
6 
4 
4 
3 
2 
1 
1 
Maximum percent inhibition at 20 \ig/m\ 
Native plasmid DNA 
33.2,25,31.8,21.7 
46,29.9,22,26.8 
45,30.1,26.7,39,26.6,32.3 
33.4,36.5,30.7,23.7 
43.6,27.3,23,30.3 
27,18.5,42.8 
26, 36.8 
27 
26.2 
ROS-plasmid DNA 
55,56.6,52.1,34 
68.5, 55, 35, 54.9 
56,52,47,53,37,57.8 
54.3,50.8,46.9,42.5 
50.2,45, 42.2, 47 
44.2, 37.2, 36.5 
47.3, 50 
45.9 
40.3 
The microtitre plates were coated with ROS-plasmid DNA (2.5 ng/ml). 
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Fig. 53. Elution profile of head and neck cancer IgG on Protein A-Agarose column. 
Inset: SDS-PAGE of purified IgG on 7.5% polyacrylamide gel. 
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Fig. 54. Band shift assay of head and neck cancer IgG binding to native plasmid DNA. 
Native plasmid DNA (0.5 i^g each) was incubated with buffer (lane 1) and 30, 
60, 90, 120 ^g of IgG through lanes 2 to 5 respectively for 2 hr at 37°C and 
overnight at 4°C. Electrophoresis was performed on 1 % agarose gel for 2 hr at 
30 mA. 
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Fig. 55. Band shift assay of head and neck cancer IgG binding to ROS-plasmid DNA. 
ROS-plasmid DNA (0.5 |ag each) was incubated with buffer (lane 1) and 30, 
60, 90, and 120 i^g of IgG through lanes 2 to 5 respectively for 2 hr at 37°C 
and overnight at 4°C. Electrophoresis was performed on 1% agarose gel for 2 
hr at 30 mA. 
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Reactive oxygen species (ROS) are continuously generated in cells by cellular 
metabolism and by exogenous agents but increases in their steady states are regarded to 
be responsible for a variety of pathological conditions, including cardiovascular diseases, 
cancer and ageing (Ames et al, 1993; Griendling and Harrison, 1999). ROS can damage 
proteins, lipids and DNA, ultimately leading to cell death. 
Hydroxyl radical is the most reactive radical of all ROS. It is formed in vivo by 
ionizing radiations (Breen and Murphy, 1995) or through Haber-Weiss or Fenton reaction 
(Mello-Filho and Meneghini, 1984a; Aruoma et al., 1991). It reacts at diffusion rates with 
virtually any molecule found in its path including macromolecules such as DNA, 
proteins, membrane lipids and carbohydrates. The uncontrolled action of 'OH radicals by 
far can have devastating effects within the body. 
Hydroxyl radical produces a large number of sugar-derived and base-derived 
products in DNA as well as DNA-protein cross links in mammalian chromatin (Von 
Sontagg, 1987; Oleinick et al, 1987; Dizdaroglu, 1992; Breen and Murphy, 1995). The 
common modified bases include 8-oxoguanine, thymine glycol, 8-oxoadenine, 5 
hydroxymethyl uracil etc (Floyd, 1990; Dizdaroglu, 1994). The radical can directly 
induce single strand and double strand breaks of DNA, cleaving the sugar-phosphate 
bond (Povirk etal, 1988; Halliwell and Aruoma, 1991). 
Oxidative damage to DNA is encountered by cellular repair systems mainly by 
base-excision repair (Wallace, 1998) and can repair excise damaged bases and sugar 
fragments from DNA (Friedberg et al, 1995). However, continuous ROS damage and 
division of cells with unrepaired or misrepaired lesions lead to mutations. Free radicals 
have long been known to be mutagenic. They act as mediators of the other phenotypic 
and genotypic changes that lead from mutation to neoplasia. Mutagenesis by ROS could 
contribute to the initiation of cancer in addition to being important in promotion and 
progression phases (Von Sonntag, 1987; Halliwell and Aruoma, 1991; Dizdaroglu, 1993; 
Epe, 1993). It is increasingly proposed that ROS plays a key role in human cancer 
development. (Totter, 1980; Ames, 1989; Oshima and Bartsch, 1994; Cerutti, 1994; Feig 
et al, 1994; Routledge et al, 1994). ROS can cause DNA base damage, strand breaks. 
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damage to tumor-suppressor genes and enhanced expression of protooncogenes (Cerutti, 
1994; Jackson, 1994). 
Systemic lupus erythematosus is a multiorgan autoimmune disease characterized 
by immune dysregulation leading to excessive production of autoantibodies, directed in 
particular towards multiple nucleic acid and nucleoprotein antigens (Kotzin, 1996). Both 
environmental and genetic factors are assumed to play important role in the pathogenesis 
of the disease. Among the various autoantibodies, anti-double stranded DNA (anti-ds 
DNA) antibodies are a recognized diagnostic hallmark of the disease associated with 
immune complex glomerulonephritis and renal dysfunction (Pisetsky et al., 1990; Kotzin, 
1996). The production of autoantibodies in SLE is thought to be antigen driven and 
involves the clonal expansion of hyperactive autoantibody producing B cells in the 
context of accompanying defects in T cell regulation (Kotzin, 1996). Antibodies to DNA 
in SLE have been extensively studied and may be specific for ssDNA, reactive with both 
ssDNA and dsDNA, or specific for dsDNA (Stollar, 1979; Worrall et al, 1990). It is the 
antibodies to native dsDNA that represent a characteristic serological finding in these 
patients and are of important diagnostic and clinical value. 
The binding diversity of lupus autoantibodies to a whole spectrum of modified 
nucleic acid conformers (Ali et al, 1991; Alam and Ali, 1992; Alam et al, 1992; 1993; 
Arif e/ al, 1994; Arjumand and Ali, 1994; Klinman et al., 1994; Moinuddin and Ali. 
1994; Ahmad et al, 1997; Garg and Ali, 1998) seems to be enormous. Anti-DNA 
production accompanies many encoimters with bacteria and viruses (Wu et al, 1997). 
Defective DNA damage processing has been reported in SLE. Indicators of oxidative 
stress, such as products of nucleic acid and lipid oxidation are elevated in SLE patients 
(Jiang and Chen, 1992; Lunec etal, 1994; Grune et al, 1997). 
In the present study 400 bp fi-agments of native calf thymus DNA were modified 
by 'OH radical generated by the UV irradiation of hydrogen peroxide at 254 nm. *0H 
caused extensive damage to DNA, leading to single strand breaks. The absorbance of 400 
bp DNA decreased at 260 nm after ROS modification compared to the native analogue. 
The hypochromicity in ROS-DNA could be a result of single strand breaks. 
The thermal denaturation profile of native and ROS-DNA showed a net decrease 
of 10°C in the Tm value for the modified DNA as compared to its unmodified conformer, 
indicating the presence of single stranded regions in the modified DNA and also a partial 
destruction in its secondary structure. Base stacking as well as hydrogen bonding are 
involved in stabilizing the native structure of DNA and their disruption by high 
temperature favours denaturation (Casperson and Voss, 1983; Thomas, 1993). The 
lowered Tm of ROS-DNA, therefore points towards the destabilization of these 
interactions and consequently helix disruption. Structural alterations are caused in ROS-
DNA due to simultaneous strand scission, generation of single-stranded regions and 
disruption of hydrogen bonding. 
The generation of single strand breaks in ROS-DNA was fiirther confirmed by 
hydroxyapatite column chromatography. Hydroxyapatite has a greater affinity towards 
rigid ordered structures than flexible, disordered ones (Bemardi 1965; 1969). The elution 
of a fraction of ROS-DNA fi-om hydroxyapatite column by the lower strength buffer (125 
mM Na-K-phosphate buffer) indicates the presence of single strand breaks and a resultant 
local perturbation in the secondary structure of ROS-DNA. Native DNA was eluted only 
by the higher strength buffer (254 mM Na-K-phosphate buffer) indicating its greater 
affinity for hydroxyapatite matrix and hence presence of a regular and intact secondary 
structure. 
Earlier studies demonstrate that the structural alteration in DNA, following 
damage by various agents, may at times be large enough to act as substrate for single 
strand specific nucleases (Kato and Fraser, 1973; Slor and Lev, 1973; Shishido and Ando, 
1974; Yamasaki et ai, 1977). Native and ROS-DNA were subjected to nuclease SI 
digestion, in order to confirm the generation of single stand breaks. The data shows 
almost total digestion of ROS-DNA on treatment with nuclease SI, while native DNA 
remain undigested. These observations clearly demonstrate that sufficient distortions are 
caused in the helical structure of DNA by 'OH radical, rendering it susceptible to 
digestions by single strand specific nuclease SI. 
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Plasmid DNA was modified by hydroxyl radical generated by the UV irradiation 
(254 nm) of hydrogen peroxide. Production o f OH radical was confirmed using mannitol 
as the specific quencher of *0H radical. 
Hydroxyl radical caused extensive damage to plasmid DNA, pBS DHsa "KS". 
Hydroxyl radical modification of plasmid DNA resulted in hypochromicity of the 
spectral curve of ROS-plasmid DNA as compared to the native plasmid DNA. This could 
be attributed to single strand breaks and modification of the nitrogenous bases, which 
results in destruction of the chromophoric groups as revealed by the hypochromicity of 
ROS-plasmid DNA. UV absorption spectra of ROS-plasmid DNA in presence of 
mannitol shows less damage, as compared to the damage obtained in its absence. This 
confirmed that the damage caused was due to production of hydroxyl radical. 
Appreciable evidence for the generation of strand breaks (single and double) in 
the plasmid DNA as a consequence of ROS modification was resolved by agarose gel 
electrophoresis. The supercoiled form of plasmid DNA becomes linearised upon ROS 
modification. Thus confirming that, generation of *0H radical results in strand breaks 
which convert supercoiled form to linear. 
The generation of single strands was further confirmed by fluorescence 
spectroscopy. Fluorescence spectra of both native plasmid DNA and ROS-plasmid DNA 
was taken using ethidium bromide. Ethidium bromide intercalates with double stranded 
DNA. The decrease in fluorescence intensity of ROS-plasmid DNA as compared to the 
native form confirms the disruption of the secondary structure of DNA upon ROS 
modification. 
Native DNA differs from other macromolecules in its lack of immunological 
activity (Madaio et al, 1984; Stollar, 1986). Immunization with single stranded DNA can 
elicit a limited antibody response, whereas double stranded RNA, RNA-DNA hybrids, 
DNA modified with drugs, hormones, chromatin or DNA in complexes with DNA 
binding proteins are effective immunogens (Stollar 1973; 1975; 1986; Anderson et al.. 
1988a; Desai et al., 1993; Moinuddin and Ali, 1994; Hasan et al.. 1995; Theofilopoulos, 
1995; Arjumand et al., 1995; 1997). Evidences suggest that bacterial DNA has potent 
immunomodulatory properties that make it an adjuvant. Bacterial DNA is mitogenic for 
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murine B cells and can induce both proliferation and antibody production (Pisetsky, 
2000). The immune stimulation by bacterial DNA results from characteristic CpG 
sequence motifs. Reactive oxygen species modified DNA have been implicated in the 
pathogenesis of SLE (Ara and Ali 1992; 1993; 1995; Ahmad et al, 1997. Cooke et ai, 
1997). Conformational variance from the B-form appears to be a prerequisite for the 
induction of antibody response (Burlingame et al., 1993; Mohan et al., 1993). 
Antibodies against ROS-modified plasmid DNA were induced in rabbits by 
immunizing with ROS-plasmid DNA complexed with methylated bovine serum albumin. 
The ROS-plasmid DNA was a potent immunizing stimulus, inducing high titre 
antibodies. The antigenic specificity of anti-ROS-plasmid DNA IgG was ascertained by 
competition binding assay. A maximum of 86% inhibition was observed with the 
immunogen. The concentration of immunogen for 50% inhibition of IgG binding to 
immunogen was observed at 1.6 ^g/ml. In addition, the induced antibodies showed lesser 
binding of 38% to the native plasmid DNA. The data indicates the higher specificity of 
the immune IgG towards ROS-modified epitopes. Modification of DNA by ROS might 
have generated potential epitopes against which the antibodies are raised. 
In order to facilitate the detection of interaction between immune IgG and 
immunogen, gel retardation assay was carried out. The results revealed a high affinity of 
anti-ROS-plasmid DNA IgG for its immunogen. However, the specific binding of anti-
ROS-plasmid DNA IgG was not observed with native plasmid DNA. These results 
further suggest that the induced antibodies react with antigenic determinants generated as 
a result of ROS-modification of DNA. 
400 bp calf thymus DNA and native human DNA showed inhibitions of 25% and 
31% respectively, whereas their ROS-modified forms showed higher inhibition of 61% 
and 65.4% respectively. These results demonstrate the preferential recognition of ROS-
modified epitopes by immune IgG. Oj" DNA however, inhibited antibody activity to a 
lesser extent possibly because damage inflicted on DNA byO^" is less severe than that 
by hydroxyl radical (Fischer-Nielson et al., 1994). Adenine, ROS-adenine and thymine 
were poor inhibitors of antibody binding to the antigen. Competitive immunoassay using 
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these as inhibitor showed inhibition of 14%, 20.2% and 29.5% respectively. In contrast to 
these ROS-thymine showed substantial inhibition of 51%. Earlier reports demonstrated 
thymine to be particularly susceptible to modification by 'OH (Hutchinson, 1985; 
Dizdaroglu and Bergtold, 1986; Breen and Murphy, 1995) generating products such as 
5,6-dihydroxy-5-6-dihydrothymine (thymine glycol), 5-hydroxy-5-6-dihydrothymine or 
6-hydroxy-5-6-dihydrothymine. The results clearly indicates that the immune IgG is 
more specific to thymine after ROS modification. 
The anti-ROS-plasmid DMA IgG also showed cross reactivity towards 
chondroitin sulphate and cardiolipin. It has been suggested that phosphate-sugar-
phosphate moiety of cardiolipin mimics the backbone of DNA, thus explaining the cross-
reactivity of immune IgG (Rauch et ai, 1984). Analysis of the data indicates that anti-
ROS-plasmid DNA IgG is polyspecific and the various cross reacting inhibitors with 
which it reacts, share a common antigenic determinant. 
SLE is a rheumatic disease characterized by varied clinical manifestations and the 
production of high titres of autoantibodies. Antibodies to dsDNA are observed in 60-70% 
of lupus patients (Tan et ai, 1982). Anti-dsDNA antibodies contribute substantial 
discriminating capacity to the diagnostic effort and are included among the classification 
criteria for SLE (Hochberg, 1977). Antibodies to dsDNA are believed to play a major 
role in inducing some of the disease manifestations of SLE, thus serve as 
immunochemical marker for the diagnosis of SLE. Polyspecific behavior exhibited by 
SLE anti-DNA autoantibodies suggests that native DNA itself may not be the 
immunogen responsible for their production and the binding of these autoantibodies to 
dsDNA may be a non-specific cross reactive event (Zack et ai, 1995). Thus, the precise 
antigen responsible for anti-DNA autoantibody production in SLE patients remains an 
enigma. 
Oxidative damage to DNA serves several pathogenic functions in SLE thereby 
implying the role of oxidative stress in the aetiology of SLE (Evans, 2000). The 
phagocytic cells release reactive oxygen species (Allan et ai, 1988), which penetrate 
cellular membranes and react with nuclear DNA (Bashir et ai, 1993). Subsequent release 
of this altered DNA during apoptosis may enable it to act as an antigen, inducing 
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antibodies cross-reacting with native DNA (Herrman et al., 1996; Casciola - Rosen and 
Rosen, 1997). 
In the present study, the possible role of ROS-modified and the unmodified 
plasmid DNA in SLE was also probed. Sera of SLE patients with high titre of anti-DNA 
autoantibodies were collected for the study. Of these, 24 SLE sera were found to show a 
higher binding with ROS-plasmid DNA as compared to native plasmid DNA. Native calf 
thymus DNA showed almost similar binding as with native plasmid DNA. When 
reactivity of native and ROS-plasmid DNA with SLE sera was probed, competition 
ELISA results showed the preferential binding of ROS-plasmid DNA over native plasmid 
DNA. The results indicate that the modified DNA is an effective inhibitor, showing 
substantial difference in the recognition of ROS-plasmid DNA over native plasmid DNA. 
Band shift assay ftulher substantiated the binding of native and ROS-plasmid DNA with 
SLE anti-native DNA autoantibodies. The strong binding potential of anti-DNA IgG 
towards ROS-plasmid DNA demonstrates the possible role of modified nucleotides in 
SLE pathogenesis. 
The presence of autoantibodies reactive towards nDNA and ROS-plasmid DNA 
in sera of patients with cancer was also studied. The study consisted of 29 sera from 
patients with various types of malignancies. All the sera showed a higher reactivity 
towards ROS-plasmid DNA. Increased levels of circulating antibodies and autoantibodies 
have been reported in sera of patients with malignancies (Anderson et al, 1988b; 
Faiderbe et al.. 1992; Chagnaud et al.. 1992; Becker et al. 1994). Elevated levels of anti-
nuclear antibodies up to 27% in cancer have been reported (Zeronski et al, 1972; 
Bunham, 1972). 
The data presented here clearly indicates the presence of circulating antibodies in 
cancer sera reactive to ROS-plasmid DNA and native plasmid DNA. Of the 4 breast 
cancer sera, all showed a higher binding to ROS-plasmid DNA as compared to the native 
form. It has been well accepted that ROS damage to DNA plays a fundamental role in 
carcinogenesis, particularly of the breast cancer (Maiins and Haimanot, 1991; Malins ./ 
al. 1996). Therefore, ROS-modification of plasmid DNA might be the contributory 
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factor in the induction and elevated levels of the circulating antibodies primarily against 
ROS-DNA but cross-reacting with native DNA. 
Cancer of head and neck also suggests oxidative damage of DNA in these 
patients. All the 4 samples showed higher recognition of ROS-plasmid DNA than the 
native DNA, thus suggesting the role of ROS damage to DNA in the development of this 
disease. 
Out of the various cancer sera tested, a large group belonged to patients suffering 
from malignancies of respiratory system, such as cancer of oral cavity and lung. 
Addiction to tobacco is the primary cause of these malignancies and leads to enhanced 
production of ROS (Nair et al, 1992; Leanderson, 1993). Higher binding to ROS-
plasmid DNA in all 6 samples of oral cavity and 2 out of 3 lung cancer samples suggests 
the involvement of ROS-plasmid DNA in the development of cancer of respiratory 
system (Wyder and Hoffman, 1994). 
Patients suffering from cancer of prostrate and gall bladder also showed higher 
reactivity towards ROS-plasmid DNA. Prostrate cancer is associated with endogenous 
cellular processes (Feig et al, 1994; Olinski et al, 1995) that lead to the production of 
various genotoxins, particularly ROS. Serum from cancer of vulva, Hodgkin's 
lymphoma and CML also showed greater recognition of ROS-plasmid DNA as compared 
to its native form. 
The data clearly support the notion of ROS damage to DNA and thus altering the 
immunogenicity of DNA, leading to generation of autoantibodies in cancer patients. The 
above statement is supported by the observation that circulating antibodies bind 
preferentially to ROS-plasmid DNA over native plasmid DNA. 
The recognition of native and ROS-plasmid DNA by cancer antibodies was 
visually detected in gel retardation assay. Based on the above studies, the following 
conclusions can be drawn: 
1. Reactive oxygen species modification of DNA resulted in the formation of 
strand breaks, disruption of hydrogen bonds and a consequent helix 
destabilization. 
22 
2. Thermal transitions show that the modified conformers are less stable as 
compared to native form. 
3. ROS-modified plasmid DNA is highly immunogenic in experimental animals. 
4. Induced antibodies are highly specific for immunogen £ind also show cross 
reactivity with native plasmid DNA. 
5.. The induced antibodies show polyspecificity. These antibodies show 
significant binding with various synthetic nucleic acid polymers. 
6. Anti-ROS-plasmid DNA recognizes the ROS-modified conformers better than 
the native conformers. 
7. The binding affinity of ROS-plasmid DNA for SLE sera is maximum whereas 
native calf thymus DNA and native plasmid DNA showed almost similar 
binding. 
8. ROS-plasmid DNA presents discriminating antigen for the binding of SLE 
autoantibodies. It is suggested that ROS modified nucleic acids might be 
challenging the immune system, leading to autoantibody production. 
9. Antibodies in sera of various cancer patients were found to be more specific 
for ROS-plasmid DNA than for its native analogue. 
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